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Myeloid derived suppressor cells (MDSCs) are heterogeneous population of 
immature cells at various stages of differentiation, characterized by the presence of 
CD11b and Gr1 in mice. They are major contributors of the tumor-induced immune 
suppression against the tumors. So far, various strategies have been introduced to 
xii 
 
overcome the endogenous MDSCs. Most of these approaches rely on the elimination 
of MDSCs and it is not clear whether tumor-reactive T cells may be differentiated 
towards phenotypes that are refractory to MDSCc. Our laboratory has previously 
shown that high affinity T cells derived from tumor-sensitized wild-type FVB mice 
and expanded ex vivo with the alternating common gamma chain cytokine 
formulation (initiation of culture with IL-7 + IL-15 followed by one day pulse with 
IL-2 and continuation of culture with IL-7 + IL-15) can successfully induce tumor 
regression in FVBN202 transgenic mouse model of breast carcinoma upon adoptive 
immunotherapy (AIT), only when combined with the depletion of endogenous 
MDSCs. In this study we have introduced a novel formulation of the sequential 
common gamma chain cytokines (initiation of culture with IL-7 + IL-15 followed by 
the expansion with IL-2 until 6 days) for the ex vivo expansion of the autologous and 
tumor-sensitized low affinity T cells derived from FVBN202 mice and further used 
for AIT. This novel formulation induced differentiation of tumor-reactive CD8+ T 
cells mainly towards effector and effector/memory phenotypes that were refractory 
to MDSCs in vitro and in vivo. AIT by using these T cells induced rejection of 
primary neu positive tumors and generated long-term memory responses against the 
recall tumor challenge. Importantly, these T cells also resulted in the inhibition of 
neu antigen negative relapsed tumor cells. Our findings in the present study provide 
a platform for AIT of breast cancer patients.         
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CHAPTER 1 Introduction 
 
           1.1. Cancer-Statistics and Challenges   
Despite extensive ongoing cancer research and newly emerging therapeutic strategies, 
cancer remains to be a devastating disease in the world. According to the American 
Cancer Society report in 2009, cancer accounts for nearly one-quarter of deaths in the 
United States, exceeded only by heart diseases.  Worldwide, one in eight deaths is due 
to cancer, exceeding the mortality rate of AIDS, malaria and tuberculosis combined. 
The corresponding estimates for total cancer deaths in 2007 were 7.6 million, or about 
20,000 cancer deaths a day, with 2.9 million in economically developed countries and 
4.7 million in economically developing countries. By 2050, the global burden is 
expected to grow to 27 million new cancer cases and 17.5 million cancer deaths. 
Moreover, the direct and indirect costs of cancer are extensive (1) and are a financial 
burden for the society. In women, breast cancer is the second most prevalent fatal 
cancer exceeded by lung cancer and followed by colon and rectum cancer. 
1.2. Breast Cancer and Importance of ErbB Family of Receptor Tyrosine Kinase- 
Structure and Function in Cancer Initiation- 
Breast cancer is the most frequently occurring cancer in women in the United States, 
with an overall risk of developing invasive breast cancer 1 in 8 (2, 3). Her-2/neu 
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(human epidermal growth factor receptor 2), is an onco-protein that upon activation 
triggers intracellular signaling events, crucial for cell growth, proliferation, 
differentiation and survival (4). It has been reported that the Her-2/neu proto-oncogene 
is amplified in 25-30% of human primary breast cancers (5), which has been associated 
with tumor aggressiveness and unfavorable clinical prognosis (6). Overexpression of 
Her-2/neu is evident by the gene amplification as well as protein overexpression. A 
variety of carcinomas including ovarian, prostate, lung, liver, kidney, bladder, and 
gastric cancer also overexpress Her-2/neu (4). Therefore, effective therapeutic 
formulation that targets Her-2/neu may be applicable to all types of carcinomas with 
the overexpression of Her-2/neu. A correlation was established between Her-2/neu 
gene amplification/Her-2/neu receptor overexpression and other positive indications of 
tumor progression such as tumor size, absence of hormone receptor expression, 
aneuploidy and proliferation index, all of which are associated with poor prognosis (7-
9). 
Her-2/neu or rat neu with 89% homology to human Her-2/neu (10) is a member of the 
epidermal growth factor receptor (EGFR) family, also known as ErbB family of 
tyrosine kinase receptors. The Epidermal Growth Factor (EGF) is known to stimulate 
epidermal proliferation and eventual keratinization. The EGFR was discovered in 1975 
as a specific target for epidermal growth factor (11, 12), and it is the first cell surface 
receptor known to be linked directly to cancer. The EGFR family encompasses 4 
members, ErbB1 (EGFR itself), ErbB2 (also known as Her-2/neu), ErbB3 and ErbB4 
(13). All members of this family are structurally related and composed of closely related 
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single chain modular glycoproteins with a heavily glycosylated extracellular ligand 
binding region (~620 residues), a single transmembrane domain (~23 residues) and an 
internal tyrosine kinase domain (~260 residues) that is flanked by juxtamembrane (~40 
residues) and a C terminal (~232 residues) regulatory regions. The extracellular domain 
(ECD) is composed of 2 homologous large domains and 2 cysteine rich domains (13). 
Sub-domains I (ECDI), located most distally from the cell membrane, together with 
sub-domain III (ECDIII), are the homologous members of the leucine rich repeat family 
and participate in binding to extracellular ligands (13-17). Sub-domains II (ECDII) and 
IV (ECDIV) are cysteine rich and ECDII acts as a dimerization arm. In the presence of 
ligands ECDII is exposed and facilitate heterodimerization with the ECDII of other 
ErbB molecules (13-15). In the absence of the ligands the ErbB molecules assume a 
“tethered” structure, and during this orientation ECDIV interacts with ECDII thereby 
blocking its dimerization interface (13-15). Her-2/neu is unique among the family with 
its ECDII dimerization arm being constitutively exposed. This structural peculiarity 
makes it accessible to other ErbB family members for heterodimer formation (18). In 
fact, it is the most highly preferred heterodimerization partner of the other ligand bound 
family members. Her-2/neu has no known direct activating ligand, which provides a 
satisfying explanation for the unique biological properties of this orphan receptor, since 
ligand binding to ECDI and ECDIII facilitates a conformational change that exposes 
ECDII in other ErbB molecules, ultimately resulting in a unique dimerization that is 
purely receptor mediated (13, 14, 16, 17). The receptor molecules of EGFR family in 
general, in the ligand-induced dimer conformation become tyrosine autophosphorylated 
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in trans. The resulting phosphotyrosine recruits the SH2 domain of multiple 
downstream signaling molecules thus initiating an array of intracellular signaling 
pathways (13). In the case of Her-2/neu, overexpression of the receptor alone favors 
increased dimerization with other ErbB family members or its homodimerization, 
thereby triggering signaling cascades that ultimately result in uncontrolled proliferation 
and cell survival (14, 19). The intracellular signaling pathway of Her-2/neu is thought to 
involve ras-MAPK, MAPK independent S-6 kinase and phospholipase c-gamma 
signaling pathways (7). The above mentioned observations explain the reasons why 
overexpression of Her-2/neu can cause cell transformation. Several cancer therapeutic 
strategies targeting Her-2/neu have been introduced in the past few years namely 
monoclonal antibody therapy, tyrosine kinase inhibitors, and vaccines. A monoclonal 
antibody Trastuzumab (Herceptin®) that was approved by the Food and Drug 
Administration (FDA) recognizes ECDIV of Her-2/neu and is effective against 30% of 
the Her-2/neu positive breast cancers, though majority of patients develop resistance 
within 9 months of treatment. Trastuzumab is not effective against Her-2/neu 
overexpressing ovarian cancers, therefore, other monocolonal antibodies that target 
different sub-domains of the Her-2/neu ECD are being developed. Among these, 
Pertuzumab recognizes ECDII and has been shown to be effective against Her-2/neu 
overexpression breast and ovarian cancer in clinical trials (20). 
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Figure 1A: Domain organization of a typical member of the Epidermal Growth 
Factor Receptor Family.  
 
The receptor is composed of an extracellular region, a transmembrane domain and a 
tyrosine kinase domain. The tyrosine kinase domain is flanked by a juxtamembrane 
region and a regulatory C-terminal region. The extracellular domain (ECD) is composed 
of four sub domains, namely Domain I (ECDI), Domain II (ECDII), Domain III 
(ECDIII) and Domain IV (ECDIV). 
 
 
Figure 1B: The structure and dimerization pattern of ErbB molecule 
 
The top panel shows ErbB2 (left) with a constitutively exposed dimerization arm 
(ECDII) even in absence of ligand whereas ErbB1, 3 and 4 adopt the “tethered” 
conformation in absence of the ligand (centre). Upon ligand binding (right) ErbB1, 3 
and 4 acquire a conformational change that exposes the dimerization arm for binding. 
The middle panel shows that ErbB2 molecule exhibiting a fixed conformation 
resembling a ligand activated state of EGFR and ErbB3 molecules.  The bottom panel 
shows ligand binding to ErbB receptors which induces the homo- and hetero-
dimerization and subsequent activation of the intrinsic kinase domain which results in 
phosphorylation of specific tyrosine residues within the cytoplasmic tail. These 
phosphorylated residues serve as docking sites for a range of proteins, the recruitment 
of which leads to the activation of intracellular signal pathways.  
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Figure 1A 
Burgess, A. W., H. S. Cho, C. Eigenbrot, K. M. Ferguson, T. P. Garrett, D. J. Leahy, M. A. Lemmon, M. X. 
Sliwkowski, C. W. Ward, and S. Yokoyama. An open-and- shut case? Recent insights into the activation of 
EGF/ErbB receptors. Mol. Cell 12(3):541-552, 2003. 
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Hynes,N.E. and H.A.Lane. ERBB receptors and cancer. The complexity of targeted inhibitors. 
Nat.Rev.Cancer 5(5):341-354, 2005. 
Figure 1B 
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1.3. Mouse Model 
The FVBN202 mouse model of neu overexpressing spontaneous mammary carcinoma 
provides a clinically relevant model for investigating the immunotherapy of Her-2/neu 
positive breast cancer. These mice develop spontaneous mammary tumors within 4-12 
months of age as a result of overexpression of the unactivated form of rat neu oncogene 
in their mammary glands under the control of the mouse mammary tumor virus 
(MMTV) promoter (21). The MMTV/unactivated neu is isogenic to the 
MMTV/activated neu except for the absence of the activating mutation in the 
transmembrane domain and the presence of a SalI restriction endonuclaese site between 
the neu cDNA and SV40 polyadenylation splicing signals. 
FVBN202 mice develop premalignant mammary hyperplasia similar to ductal 
carcinoma in situ (DCIS) prior to the development of spontaneous carcinoma within 
1.5-2 months of age. Spontaneously arising mammary tumors are harvested from these 
mice and processed in the laboratory to establish neu + mouse mammary carcinoma cell 
lines, referred to as MMC. The endogenous overexpression of neu oncogene in these 
transgenic mice makes them immunologically tolerant to neu oncoproteins. This makes 
the animal model clinically relevant, mimicking the normal condition of human breast 
cancer, where malignancy develops from “self” tissues thereby escaping the body’s own 
immune system. The T cells harvested from these mice are of low affinity for the neu 
tumor antigen. On the contrary, wild type FVB mice do not express the rat neu 
oncogene, so the immune system of these mice can exhibit robust responses, when the 
animals are inoculated with neu+ mouse mammary carcinoma (MMC) tumors derived 
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from spontaneous mammary tumor of FVBN202 mice. The animals can subsequently 
reject MMC, because of harboring the neu specific T cells that express high affinity 
receptors for the neu antigen.  It has been reported previously, that FVBN202 mice 
show an increased level of myeloid-derived suppressor cells (MDSCs) during the 
initiation and establishment of spontaneous breast carcinoma (22). Figure 1C shows the 
correlation of the increased abundance of CD11b+Gr1+ MDSCs along with the 
progression and establishment of spontaneous breast carcinoma. Slides show the section 
of the normal mammary duct followed by the gradual proliferation of the epithelial 
layer during premalignant atypical ductal hyperplasia (ADH) and finally with the 
establishment of malignant breast tumor. Uncontrolled proliferation of the epithelial 
layer coincided with the increased level of MDSCs (22).  
10 
 
Figure 1C: Increased level of MDSCs along with the progression and 
establishment of breast carcinoma 
 
The figure shows an increased CD11b+Gr1+ MDSCs along with the gradual 
progression and establishment of mammary carcinoma. Starting from the normal level 
in FVBN202 mice with healthy mammary epithelial ducts, the MDSCs show consistent 
increase during the atypical ductal hyperplasia (ADH) and invasive breast cancer. 
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Figure 1C 
 
 
 
 
 
 
 
 
  
 
 
 
Kmieciak et al. “Danger signals and nonself entity of tumor antigen are both required for eliciting effective 
immune responses against HER-2/neu positive mammary carcinoma: implications for vaccine design.”. l Cancer 
Immunol Immunother. 57: 1391-1398, 2008. 
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1.4. Myeloid -Derived Suppressor Cells (MDSCs) – How do they abrogate anti-
tumor immune responses in vivo 
Tumor development is often accompanied by a peculiar alteration of hematopoesis that 
leads to a progressive accumulation of myeloid cells in bone marrow, blood, spleen and 
at the tumor site. These cells share the markers CD11b and Gr1 and their accumulation 
correlates with the inhibition of T cell responses to antigenic stimulation both in vivo 
and in vitro. CD11b+ Gr1+ cells are heterogenous and are commonly known as myeloid 
derived suppressor cells (MDSCs).  The abundance of this cell population is correlated 
with many types of cancer namely murine colon carcinoma MCA-26, Lewis lung 
carcinoma, highly metastatic breast carcinoma, 4T1, neu+ breast carcinoma  and 
melanoma (B16) (23, 24-27). Increased abundance of circulating MDSCs correlates 
with clinical cancer stage and metastatic burden of breast cancer. Stage IV patients with 
extensive metastatic tumor burden had the highest percentage and absolute number of 
MDSCs (28). Increased abundance of MDSCs during tumor progression is associated 
with enhanced myelopoesis, because soluble factors secreted from tumors including 
GM-CSF and VEGF are known to stimulate myelopoesis or block the maturation of 
hematopoetic progenitor cells, respectively (23, 29). It is still not clear which signaling 
pathway is specifically involved in the induction of MDSCs. A number of pathways 
including STAT1, STAT3, c-kit ligand/ receptor have been suggested to be responsible 
for induction of MDSCs.  The heterogenous population of MDSCs characterized by 
CD11b+Gr1+ actually represents a macropopulation. Different epitopes of the Gr1 
molecules have been identified, namely Ly6G and Ly6C in different subsets of MDSCs 
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characterized by different functional attributes (25, 30, 31). The Ly6 family members 
are cysteine rich molecules that are glycosyl phosphatidylinositol (GPI)-anchored to the 
cell surface; it has recently been reported that expression of Ly6G represents a 
granulocytic phenotype whereas Ly6C correlates with a monocytic phenotype. The 
mononuclear cell MDSCs are akin to inflammatory monocytes whereas polymorpho 
nuclear (PMN) MDSCs are closer to immature neutrophils. Blocking IFN-γ or 
disrupting STAT1 impaired suppression by the former while IFN-γ was required for 
suppression by PMN MDSCs (25, 30). Recent reports reveal that the monocytic 
phenotype contributes to the suppressive function of MDSCs (32, 33).  
The exact mechanism of T cell suppression by MDSCs remains elusive. It has been 
reported that MDSCs can acquire endothelial cell property in tumor microenvironment 
and supports angiogenesis, thereby favoring tumor growth while ignoring the immune 
sentinels. They are also known to cause apoptotic death of CD8+ T cells (34). 
Gabrilovich et al. have shown antigen specific contact-dependant suppression of T cells 
by MDSCs. They showed that Gr1+ cells express myeloid cell marker and MHC class I 
but lack MHC class II and do not affect T cell proliferation or IL-2 production induced 
by Concanavalin A or by MHC class II but they do exert a detrimental effect on the 
number of IFN-γ producing CD8+ T cells in response to specific peptides presented by 
MHC class I (35). Other reports reveal that MDSCs may work through downregulation 
of T cell receptor (TCR) zeta chain and can cause dysfunction of T cells described in 
cancer, infectious diseases and autoimmune disorders (36). Morales et al. also reported 
that MDSCs inhibit T cell activation in FVBN202 mice in a contact-dependent manner 
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(37). Another probable mode of suppression by MDSCs has been argued to be 
dependent on the production of nitric oxide (NO) as well as other soluble factors. It has 
been shown that suppression is due to the impairment of IL-2 receptor signaling 
pathways mediated by and requires NO, which is secreted by MDSCs in response to 
signals from activated T cells, including IFN-γ and a contact-dependent stimulus (38). 
Gabrilovich et al. proposed that antigen specific CD8+ T cell tolerance is one of the 
major mechanisms of tumor escape. They have shown that the tolerance is induced by 
MDSCs. They have found that MDSCs directly disrupt the binding of the specific 
peptide-MHC complex dimers via nitration of tyrosines within the TCR/CD8 complex, 
which results in the inability of CD8+ T cells to respond to the specific peptides. 
Nitration of the TCR by MDSCs is thought to be induced by hyperproduction of 
reactive oxygen species (ROS) and peroxinitrite during cell-cell contact (39). Some 
reports showed inhibitory effect of arginase I produced by MDSCs. Arginase I 
metabolizes L-arginine to urea and ornithine whereas nitric oxide synthase 2 converts it 
to citrulline and NO. Depletion of L-arginin by any one of these pathways results in T 
cell dysfunction. High arginase activity is reported in lung and colon cancer (23, 27). 
The same group confirms that MDSC-mediated down regulation of L-selectin to be a 
major cause of T cell suppression as T cells must express L-selectin (high) in order to 
home to lymph nodes and sites of inflammation where they encounter antigen and are 
activated. This downregulation perturbs T cell trafficking patterns thereby inhibiting T 
cell activation (40, 41). Although several groups have proposed various mechanisms of 
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suppression by MDSCs, the exact mode of action remains unclear. It is likely that 
different mechanisms of suppression exist in different cancer models. 
1.5. Cancer Therapeutics- An overview of adoptive immunotherapy 
Paul Ehrlich was one of the first to conceive the idea that the immune system could 
repress a potentially “overwhelming frequency” of carcinomas arising from ‘self’ 
tissues. To a large extent, the revisiting of Ehrlich’s proposal had to await the 
maturation of the developing field of Immunology. In 1950, the work of Medawar and 
colleagues clarified the critical role of cellular components of immunity in mediating 
allograft rejection. This work cast doubt on data that were used to argue for the 
existence of tumor antigen. Although it was generally accepted that the immune 
response was capable of recognizing and destroying transplanted tumors derived from 
outbred strain of mice, it soon became clear that the underlying mechanism was that of 
allograft rejection rather than tumor specific rejections. With the introduction of inbred 
strains of mice, it became clear that the syngeneic tumor transplant can be 
immunologically distinguishable from the normal “self” entities. The endogenous 
immune system components recognizing and abrogating the nascent transformed cells 
were described as “immunosurveillance” by Sir Macfarlane Burnet and Lewis Thomas. 
They speculated that lymphocytes acted as sentinels in recognizing and eliminating 
continuously arising nascent transformed cells and that tumor cell specific neoantigens 
could provoke an effective immunologic reaction that would eliminate cancer 
development (42, 43). 
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Along this line of thought Dighe et al. reported that endogenous production of IFN-γ 
can protect the host against growth of transplanted tumors along with the formation of 
the primary chemically induced and spontaneous tumors (43). It was shown that 
administration of the neutralizing mAbs against IFN-γ into mice transplanted with Meth 
A tumors blocked LPS-induced tumor rejection. It was also proved that transplanted 
fibrosarcomas grew faster in mice treated with IFN-γ blocking antibodies (43, 44). 
Early studies identified perforin (Prf) as a critical cytolytic molecule in the primary 
host’s anti-tumor responses. After challenge with Meth A tumors, Prf-/- mice formed 2-
3 times more tumors than wild type mice. In addition 50% of aging Prf-/- C57BL/6 
mice developed spontaneous disseminated lymphomas as compared to 1/16 wild type 
mice (42, 43).  
Availability of immune deficient mice allowed testing of tumor immunosurveillance 
hypothesis. Genetically manipulated mice lacking recombinase activating gene, RAG-2 
or its obligate partner RAG-1 cannot somatically rearrange lymphocyte antigen 
receptors, and thus cannot produce peripheral αβ T cells, B cells, NKT cells or γδ T 
cells. RAG-2 expression is limited to the cells of lymphoid system; therefore RAG-2-/- 
mice provide an appropriate model to study the effect of host cell lymphocyte 
deficiency on tumor development. It has been shown that following subcutaneous 
injection of Meth A tumor cells, 129/ SvEv RAG-2-/- mice developed tumor at the 
injection site faster than the wild type control group.  NK and NKT cells also participate 
in cancer immunoserveillance. C57BL/6 mice, depleted of both natural killer and 
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natural killer T cells using the anti-NK1.1 mAb, were two to three times more 
susceptible to Meth A-induced tumorigenesis (43). 
Presence of tumor immunosurveillance supported by the above-mentioned evidences 
provides a platform for immunotherapy of cancers. This suggests that cancer patients or 
tumor-bearing animals harbor tumor-reactive T cells that, if expanded ex vivo, can result 
in tumor regression upon adoptive T cell immunotherapy (AIT) (45). This method has 
gained some success in melanoma and in the treatment of patients with cancers 
expressing viral antigen such as Epstein Barr Virus (46).   
T cells for AIT can be harvested from various sites from the tumor-bearing hosts, 
including peripheral blood, tumor biopsies, resected lymph nodes, malignant effusions 
and spleens. Obtaining T cells from the peripheral blood may be easier, but higher 
frequency of tumor reactive T cells can be found in tumor biopsies (tumor-infiltrating 
lymphocytes, TIL) (47). However, harvesting sufficient number of TIL can be difficult, 
though this approach has been used successfully in patients with melanoma (47). 
Successful AIT depends on the type of T cells transferred, their effector functions, 
ability to reach tumor location and the ability of the cells to overcome any tolerance or 
immune suppression in the host. The immunogenic potential of the tumor antigen, size 
and location of tumor, and the regimen used for of the ex vivo expansion of autologous 
T cells determine efficacy of the therapy. Three major criteria for successful AIT are 
(48, 49): 
• Sufficient numbers of T cells with high reactivity against the tumor in vivo  
• Trafficking of T cells to and infiltrating in the tumor stroma  
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• Activation at the tumor site to manifest appropriate effector mechanisms such as 
direct lysis or cytokine secretion capable of tumor destruction 
It has been shown that efficacy of AIT depends on T cell phenotype. Terminally 
differentiated CD8+ T cells were nearly 100- fold less effective in vivo on a per cell 
basis than T cells at an early stage of differentiation. Less differentiated T cells have 
high proliferation potential and are less prone to apoptosis than more differentiated cells 
and have a higher ability to respond to homeostatic cytokines as they express receptors 
IL-7 Rα chain (45). For an effective and successful AIT, T cells should possess effector 
functions and the ability to generate memory responses (50). The major cytotoxic 
function of the CD8+ T cells demands direct cellular contact with the target cells. To 
induce the tumor specific cell death, the effector CD8+ T cells should reach the tumor 
site. This potential extravasations’ capacity depends on their ability to adhere to 
endothelial walls while withstanding shear stresses exerted by flowing blood. The 
tethering and rolling mechanism is governed by the selectin family (51). It has been 
reported that loss of expression of the lymphoid homing molecules such as CD62L or 
CCR7 and acquisition of CD44 expression can be associated with increased anti-tumor 
effects of adoptively transferred T cells (45). Moreover, expression of CD44 has been 
shown to be the most potent stimulator of Fas ligand expression on human T cells (52) 
which in turn may induce apoptosis in Fas positive target cells. 
Previous preclinical studies indicated that immune ablation is an effective 
preconditioning regimen that can increase T cell responses after adoptive 
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immunotherapy, as lymphodepletion increases the efficacy of transferred T cells. 
Transfer of small numbers of antigen-specific T cells into a lymphopenic host results in 
the expansion and activation of the transferred T cell population, known as homeostatic 
proliferation. Adoptively transferred antigen-specific T cells represent a small portion 
of the total T cell population residing in the host. Host mediated inhibitions of  the 
proliferation of  adoptively transferred T cells might involve direct cellular contact or 
competition between transferred and endogenous host T cells for a limited amount of 
resources such as cytokines that are required to support transferred T cells homeostasis. 
This is known as the “cytokine sink” effect. Lymphodepletion can overcome cytokine 
sink effects and also decrease the competition at the surface of antigen-bearing antigen 
presenting cells (APC). Gattitoni et al. reported that a lymphopenic environment 
enables tumor-reactive T cells to destroy large tumors more effectively (45).  The same 
group has also reported that though lymphodepletion reduces the number of APC in 
vivo, it is also linked to the increasing the number of mature activated APCs which can 
facilitate the activation of transferred cells (45). To create a lymphopenic host 
environment, several methods including total body irradiation, genetic alteration and 
chemotherapy can be applied. In this study we have used cyclophosphamide (CYP) for 
lymphodepletion. CYP is a synthetic antineoplastic drug and an alkylating agent that 
interferes with the growth of rapidly proliferating cells (53). CYP is also known to 
remove tumor- induced suppressor T cells. The above discussion clearly depicts that the 
elimination of the host immune suppressive environment is a primary pre-requisite for 
effective AIT. The MDSCs are known to be a major contributor to the tumor associated 
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immune suppression in a number of carcinomas. Tumor cells secrete immune 
suppressive cytokines such as IL-10, TGFβ and VEGF. Tumors express 
immunosuppressive enzyme indoleamine 2,3-dioxygenase which is involved in 
tryptophan metabolism. This enzyme appears to exert its suppressive effect through 
depletion of tryptophan and production of anti- inflammatory tryptophan metabolites 
(47). All these suppressive elements which can abrogate T cell functions should be 
eliminated prior to AIT. 
Though several ways have been introduced to circumvent these endogenous MDSCs, 
none of them has achieved complete success.  The abundance of these suppressive cells 
in the tumor microenvironment remains a critical challenge for successful AIT. 
1.6. Bryosatin-1/Ionomycin treatment and application of novel cytokine 
formulation for the ex vivo expansion of tumor-reactive T cells prior to AIT 
Bryostatin-1 belongs to a class of macrocyclic lactones derived from the marine 
bryozoans, Bugula neritina. It binds to the regulatory domain of Protein Kinase C 
(PKC) and governs its activation as well as inhibition. Short-term treatment with 
Bryostatin-1 activates PKC while long exposure may have a detrimental effect (37). 
Ionomycin is a calcium ionophore that increases the intracellular Ca2+ concentration, 
which acts as a second messenger in various signaling cascades (54). The treatment 
with Bryostatin-1 and Ionomycin (B/I) induces selective activation of tumor-specific T 
cells without the need for identification of tumor antigen (55). Exposure to both 
bryostatin-1 and ionomycin (B/I) mimics signaling through the CD3/TCR complex and 
leads to activation and proliferation of effector T cells (55).  
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Adoptive immunotherapy of cancer patients utilizes the ex vivo expansion of tumor-
reactive T cells by using cytokines or other pharmacological agents to generate a large 
number of such immune effector cells (56). Among the common gamma chain (γc) 
cytokines (IL-2, IL-4, IL-7, IL-9, IL-15, IL-21) mainly IL-2, IL-7, IL-15, and/or IL-21 
have been used to improve the efficacy of AIT. The common γ chain component of the 
receptors of these cytokines stimulates MAP kinase and PI3 kinase pathways that result 
in anti-apoptotic and mitogenic signals (57).  
The endogenous naïve T cells characterized by the presence of CD45RA can 
differentiate into quiescent memory cells bearing the characteristic of CD45RO surface 
protein and effector cells when first encounter the antigen. The quiescent memory cells 
may also arise from the differentiation of effector cells following activation. There are 
two types of memory T cells. Central/memory T cells are characterized by the 
expression of CD44 and CD62Lhigh whereas effector/memory T cells are characterized 
by the expression of CD44 and CD62Llow. The latter mature rapidly into effector cells 
after re-stimulation and secrete large amounts of IFN-γ or IL-4 (58). The ex vivo 
manipulations of T cells during the expansion can preferentially support the survival 
and proliferation of these various effector and memory phenotypes of T cells. 
IL-2 is the major T cell growth factor cytokine that is produced by activated T cells. 
The IL-2 receptor is expressed by activated T cells, activated B cells and NK cells. The 
receptor comprises three polypeptide subunits: IL-2 receptor α chain (CD25), IL-2Rβ 
chain (CD122) and IL-2Rγ chain (CD132). IL-2Rβ and γ chains participate in signal 
transduction whereas the α chain augments binding affinity for IL-2 (55). IL-2 is known 
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to cause activation-induced cell death (AICD), and it preferentially supports 
differentiation of CD8+ T cells towards effector and effector/memory phenotypes by 
down regulation of the lymph node homing receptors CD62L (59, 55). Culture of B/I 
activated human T cells from healthy donors with IL-2 ex vivo resulted in the de novo 
generation of the CD4+CD25+ FoxP3+ T cells without any detectable suppressive 
function (60). 
IL-7 is the hematopoietic growth factor cytokines which is secreted by the stromal cells, 
epithelial cells and fibroblasts but is not produced by lymphocytes. The receptor for this 
cytokine is expressed by T cells, pre-B cells and dendritic cells (DCs). IL-7 receptor 
consists of an α chain (CD127) and shares common γ chain (CD132) with IL-2 
receptor. IL-7 is crucial for the survival and homeostatic expansion of naïve and 
memory CD8+ T cells. Injection of IL-7 results in the expansion of both CD4+ and 
CD8+ T cells as well as the relative reduction of CD4+ Tregs (55, 61). 
IL-15 is produced by monocytes, dendritic cells (DCs) and epithelial cells. IL-15 
receptor consists of an α subunit and shares common β and γ subunits with the IL-2 
receptor. IL-15 receptor is expressed by T cells and NK cells. IL-15 induces expression 
of anti-apoptotic Bcl-2 as well as inhibition of pro -apoptotic Bim in CD8+ T cells 
expressing the receptors for IL-7, thereby decreasing AICD in those specific subsets of 
CD8+ T cells (62). IL-15 is known to favor the differentiation and proliferation of the 
CD8+ central memory subset of T cells. While IL-7 and IL-15 are responsible for 
supporting the primary memory CD8+ T cells, only IL-15 is known to support the 
secondary memory phenotypes (63). This cytokine is also reported to render T 
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effector/memory cells refractory to the suppressive function of Tregs via activation of 
the PI3 kinase cascades but does not involve the rescue of those T cells from apoptosis 
(64). IL-15-expanded CD8+ T cells display only effector functions in vitro but are 
highly effective in vivo. This is likely because the IL-15-induced differentiation of T 
central/memory subsets are responsible for generating prolonged memory responses in 
vivo whereas the effector T cells undergo apoptosis after several cycles of proliferation 
or cytolytic function against tumor in vitro (55). 
In this study we have aimed to introduce a novel cytokine regimen for the ex vivo 
expansion of T cells that can render the T cells refractory to the inhibitory effects of 
MDSCs and generate long-term memory responses following AIT. 
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CHAPTER 2 Materials and Methods 
 
Mouse model 
FVBN202 transgenic female mice (Charles River Laboratories) were used between 6 to 
8 weeks of age throughout these studies. These mice overexpress an unactivated rat neu 
transgene under the regulation of MMTV promoter (21). These mice develop 
premalignant mammary hyperplasia similar to ductal carcinoma in situ (DCIS) prior to 
the development of spontaneous carcinoma (22). The studies have been reviewed and 
approved by the Institutional Animal Care and Use Committee (IACUC) at Virginia 
Commonwealth University. The mice were sacrificed before they attained a tumor 
volume of 2000mm³.  
Tumor cell lines 
The MMC cell line was established from a spontaneous tumor harvested from an 
FVBN202 transgenic mouse as described previously (65). The antigen negative variant 
(ANV) cell line, characterized by a loss of neu expression, was derived from a relapsed 
MMC tumor in the FVB strain as previously described (65). Both cell lines were 
maintained in RPMI 1640 supplemented with 10% fetal bovine serum (FBS). Mice 
were challenged with 3-5x106 tumor cells by subcutaneous (s.c.) inoculation wherever 
indicated in this study. 
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Expansion of effector T cells derived from FVBN202 mice 
Female FVBN202 mice were inoculated with 4X106 MMC cells and the splenocytes 
were harvested after 10-21 days. Splenocytes (106cells/ml) were stimulated in a warmed 
complete medium containing 15% FBS with Bryostatin-1 (5nM) and Ionomycin 
(10nM) along with 80U/ml of IL-2 (Peprotech) for 16 hours. Cells were washed three 
times and cultured at 106 cells/ml in complete medium (RPMI-1640 supplemented with 
100U/ml of penicillin, 100µg/ml streptomycin, 10% FBS, glutamine and β- 
mercaptoethanol) with 10-20ng/ml of IL-7 and IL-15 (Peprotech). After 24 hours 
20U/ml of IL-2 was added to the medium. On the next day cells were washed three 
times and cultured (106cells/ml) in complete medium with 40U/ml of IL-2. Cells were 
counted and cultured at 106cells/ml in complete medium with 40U/ml of IL-2 every 
other day for a total of 6 days.  
Adoptive immunotherapy 
24 hours prior to adoptive immunotherapy (AIT), FVBN202 mice were treated with 
Cyclophosphamide (CYP, 100mg/Kg) by intraperitoneal (i.p) injection in order to 
induce lymphopenia. Mice were challenged with 3X106 MMC cells (s.c.) and then 
received 70X106 ex vivo expanded T cells by tail vein (i.v) injection later on the same 
day. Tumor growth was monitored by digital calipers and tumor volumes were 
calculated by: Volume (v) = [L (length) x W (width) ²]/2. Blood was collected from the 
orbital sinus to determine the level of circulating CD11b+Gr1+ cells by flow cytometry. 
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At the termination of the experiments, splenocytes were harvested and stained using the 
appropriate antibodies for several surface markers and internal molecules. 
Cytotoxicity assay 
Freshly harvested lymphocytes or ex vivo expanded T cells were cultured with MMC or 
with CFSE labeled ANV at 10:1 ratio, in 3 ml complete medium (RPMI-1640 
supplemented with 100U/ml of penicillin, 100µg/ml streptomycin, 10% FBS, glutamine 
and β- mercaptoethanol) and 20U/ml of IL-2 (Peprotech) in 6 well culture dishes. Prior 
to co-culture, ANV cells were stained with CFSE, to gate out the CFSE+neu- ANV 
population for estimating viability of the tumor cells. After 48 hours, MMC cells were 
harvested and stained for neu (anti-c-Erb2/c–Neu, Clone-4, Calbiochem) along with 
FITC anti mouse IgG, Annexin V-PE and Propidium Iodide (PI) according to 
manufacturer’s protocol (BD Pharmingen). In case of ANV, neu staining was omitted. 
Flow cytometry was used to analyze the viability of neu positive cells. 
CFSE staining  
5X10⁶ ANV cells were resuspended in 5 ml of HBSS and spun for 10 minutes at 1200 
rpm at 4⁰C. The HBSS was discarded and cells were stained with 1.5µM of CFSE in 1 
ml HBSS for 5 minutes at room temperature in the dark. After incubation cells were 
washed with 1 ml of FBS, followed by three more washes with HBSS+10% FBS. 
Finally cells were resuspended in complete media and desired numbers of cells were 
used for cytotoxicity assay.  
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Flow cytometry 
 Flow cytometry analyses were performed as standardized by our laboratory. The 
freshly isolated spleens were homogenized into a single cell suspension and red blood 
cells were lysed using 1X ACK (NH4Cl, KHCO3, EDTA.Na2.2H2O) lysis buffer for 6 
minutes at room temperature. Cells were washed with 2 volumes of RPMI1640 
supplemented with 10% FBS, and then resuspended in Flow Cytometry cell staining 
buffer (1X PBS with 1 % FBS and 0.1% of sodium azide). Cells were counted and 
aliquoted into each sample tube (10⁶ cells/tube). The splenocytes were used either 
freshly isolated from the mice or after co-culturing for 24 hours with and without 
MMC; or after a 6-day expansion with a special cytokines regimen. Non-specific 
binding to Fc receptors was blocked with anti-CD16/32 antibody (Biolegend, San 
Diego, CA) for 20 minutes on ice. Cells were stained with surface antibodies namely 
against CD4 (GK1.5), CD8 (53-6.7), CD3 (145-2C11), CD69 (H1.2F3), CD11B 
(M1/70), Gr1 (RB6-8C5), Ly6G (1A8), CD62L (MEL-4) and CD44 (IM-7) and 
incubated on ice in the dark for 20 min. All antibodies were used at the manufacture’s 
recommended concentration. Cells were washed twice and fixed with 1% 
paraformaldehyde. For internal staining with anti-perforin (eBioOMAK-D) antibody 
(eBioscience), FoxP3 Fix/ Perm Buffer system was used according to the 
manufacturer’s protocol (Biolegend, San Diego, CA). For Granzyme-B and IFN-γ 
(XMG1.2) (eBioscience) staining, cells already stained for extracellular molecules were 
fixed with 2.5% paraformaldehyde for 10 min on ice, permeabilized by washing with 
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1ml and then with 2ml of 0.1% saponin buffer, and stained with internal antibodies for 
30 minute on ice in the dark. Especially for IFN-γ staining, transport blocker 
(Monensin) was added to the growing cell culture medium 4 hours prior to staining. 
Lastly, cells were washed twice with normal cell staining buffer and resuspended in 500 
µl of the same. For Annexin V staining, after cells were stained for respective surface 
markers followed by a wash with Flow Cytometry cell staining buffer, they were 
washed again with 1X Annexin V buffer (BD Pharmingen) and the Annexin V staining 
protocol was followed according to manufacturer’s recommended protocol. Samples 
were run on a Beckman Coulter FC 500 and analyzed using Summit version 4.3 
software.  
IFN-γ ELISA 
Tumor-sensitized freshly isolated effector lymphocytes or ex vivo expanded T cells 
were cultured in complete medium at a 10:1 ratio with irradiated MMC cells for 24 
hours. Supernatants were collected and stored at-80⁰C until used. IFN-γ was detected 
using a Mouse IFN-γ ELISA set (BD Pharmingen) according to the manufacture’s 
protocol. 
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Protein ELISA 
ELISA was performed as previously described by our group (37). Blood was collected 
from experimental animals from the retro-orbital sinus, allowed to sit at room 
temperature for 10 minutes, and then spun for 10 minutes at 10,000 rpm. Serum was 
harvested and stored at -80⁰C until used. For measuring the antibody response against 
neu, 96 well plates were coated with 10 µg/ml of the ECDII and incubated overnight at 
4⁰ C. Plates were washed with PBS+0.05% Tween-20 and blocked with 2% skim milk 
for one hour. After washing, 5 and 50-fold serial dilutions of the sera were added 
(100µl/well) and incubated for 2 hours at room temperature. Horse-radish-peroxidase 
(HRP)-conjugated anti-mouse IgG1 was added at a 1:2000 dilution for 1 hour. Plates 
were washed and reactions developed by adding 100µl/well of the TMB Microwell 
peroxidase substrate (Kierkegaard & Perry). The reaction was stopped with 2M H2S04, 
and the O.D. read at 450 nm. Mean antibody titers were calculated. 
Isolation of Myeloid-Derived Suppressor Cells (MDSCs) in vitro 
MDSCs were isolated from tumor-bearing FVBN202 animals using an EasySep PE 
selection kit from StemCell Technologies following manufacturer’s protocol. For the 
isolation purpose, cells were stained with Gr1-PE antibody (Biolegends, San Diego, 
CA). 
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Suppression assay 
In suppression assay T cells were cultured in the presence of isolated Gr1-PE labeled 
MDSCs in a ratio of 2:1. Such mixed cell population was co-cultured with MMC at a 
ratio of 10:1:5 of Effector:Target:MDSC cells. Flow cytometry analysis was performed 
to examine various surface markers and internal molecules expressed by T cells upon 
stimulation/suppression. Supernatants from these co-cultures were collected for IFN-γ 
ELISA. For cytotoxicity assay, the cell population (T+MMC+MDSC) was stained with 
purified mouse monoclonal antibody against rat neu (anti-c-Erb2/c–Neu, Clone-4, 
Calbiochem) along with FITC- anti mouse IgG, Annexin V-PE  and Propidium Iodide 
(PI) according to manufacturer’s protocol (BD Pharmingen). 
Tumor challenge studies 
FVBN202 mice received MMC inoculations earlier the same day prior to receiving 
AIT. After successful rejection of primary tumors, they were re-challenged for second 
(n=3) and third (n=1) time on day 23 and day 61, respectively, with 5 X10⁶ MMC by 
s.c. inoculation. The recipients were also challenged with 4X10⁶ ANV (n=2) on day 50. 
Subsequent tumor inoculation was done on the contralateral side. Tumor growth was 
monitored at regular intervals. 
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Statistical analysis 
Graphical data are presented as averages with standard errors. Statistical comparisons 
between groups were made using Student’s T test with P< 0.05 being statistically 
significant.  
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CHAPTER 3 Study Rationale and Results 
 
Study Rationale 
Our laboratory has had a longstanding interest in developing an effective means of 
treating neu positive mammary tumors by using tumor-specific T cells. The FVBN202 
mouse model is clinically relevant for investigating adoptive immunotherapy (AIT) 
because of endogenous expression of rat neu oncoprotein. These transgenic mice 
develop atypical ductal hyperplasia (ADH) preceding the initiation and establishment of 
spontaneous breast carcinoma (21). Our laboratory has already shown ADH coincided 
with elevated levels of MDSCs in FVBN202 mice, which in turn resulted in the failure 
of AIT against mammary carcinoma (22, 37). Figure 1C shows the correlation of the 
increased abundance of CD11b+Gr1+ MDSCs along with the progression and 
establishment of spontaneous breast carcinoma. Uncontrolled proliferation of the 
epithelial layer was associated with the increased level of MDSCs (22). Previous 
attempts in our laboratory to use AIT to cure neu+ tumors in FVBN202 mice have 
proven unsuccessful, despite the fact that highly active effector T cells were obtained 
from wild type FVB mice that could successfully reject the neu+ tumor challenge. 
Efforts to identify the reasons lead to the understanding of the key inhibitory role of 
CD11b+Gr1+ MDSCs in FVBN202 mice. Adoptive transfer of high affinity T cells 
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derived from wild type FVB mice, activated with Bryostatin-1/Ionomycin (B/I) and 
expanded with the alternating common gamma chain cytokines (culture of T cells with 
IL-7 + IL-15 for 24 hours after the B/I activation followed by the overnight pulse with 
IL-2 and continuation of the culture with IL-7 + IL-15) ex vivo resulted in tumor 
rejection, only when combined with the depletion of MDSCs in vivo (37).  However, 
non-self source of T cells (from wild type FVB into FVBN202 mice) reduced clinical 
application of the treatment. Therefore, in the present research we used autologous low 
affinity T cells for the AIT of FVBN202 mice and developed an ex vivo protocol for the 
expansion of these T cells which render them refractory to MDSCs. We first tested an 
alternating common gamma chain cytokine protocol and then improved it into a 
sequential cytokine formulation (IL-7+IL-15 followed by IL-2). We hypothesized that 
initiation of culture with IL-7 and IL-15 would support the differentiation of tumor-
reactive memory T cells and continuation of the culture with IL-2 would result in the 
induction of activation-induced cell death (AICD) in fully differentiated T cells, 
rescuing early differentiated T cells from apoptosis. AIT by means of these T cells at 
their early stage of differentiation would induce robust tumor rejection and protect 
animals against recall tumor challenge by generating memory responses.  
Alternating common gamma-chain cytokines expanded tumor-reactive T cells that 
failed to overcome MDSCs in vivo following AIT 
Splenic T cells were isolated from tumor-bearing female FVBN202 mice and expanded 
ex vivo with an alternating gamma chain cytokine formulation 
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(IL7/IL15→IL2→IL7/IL15) following B/I activation (37). This protocol resulted in a 
2.6 and 4-fold expansion of splenocytes on day 7 compared to day 0 and post-B/I 
activation respectively (Figure 2). The B/I activation resulted in a significantly 
decreased splenocytes from 72 million to 46.94 million followed by a consistent 
expansion attaining 188.3 million cells on day-7. Figure 3 shows the proportions of 
CD8+ and CD4+ T cells from freshly isolated and ex vivo expanded lymphocytes. 
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Figure 2: Ex vivo expansion of splenocytes with alternating (IL-7/IL-15→IL-
2→IL-7/IL-15) gamma chain cytokines 
Spleen harvested from MMC-sensitized large tumor-bearing (tumor volume≤2000mm³) 
female FVBN202 mouse was crushed and processed to yield single cell suspensions 
which were subjected to a 7-day expansion with the alternating gamma chain cytokines. 
Splenocytes were incubated with 5nM Bryostatin-1 and 10nM Ionomycin along with 80 
U/ml of IL-2 in complete medium for 16 hours followed by expansion with IL-7/IL-15 
(10ng/ml), alternating with IL-2 (40U/ml) and again with IL-7/IL-15. The figure shows 
the fold increase of T lymphocytes at different time intervals during the expansion 
protocol. Cell counts were determined by trypan blue exclusion. 
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Figure 2 
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Figure 3: Expansion of splenocytes with the alternating gamma chain cytokines 
results in the expansion of CD8+ and CD4+ T cells 
Spleen harvested from MMC sensitized large tumor-bearing (tumor volume≤2000mm³) 
female FVBN202 mouse was crushed and processed to yield single cell suspensions 
which were subjected to a 7-day expansion with alternating gamma chain cytokines. 
The figure shows the percent total population of the CD8+ and CD4+ T cells before and 
after the expansion with the alternating gamma chain cytokine formulation. 
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Figure 3 
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Freshly isolated splenocytes contained 3.72% and 11.22% CD8+ and CD4+ T cells, 
respectively. Culture with the alternating gamma chain cytokines resulted in increase in 
the T cell subsets. CD8+ and CD4+ T cells expanded 9.27 and 3.48 fold, reaching 
34.51% and 39.05%, respectively.  
In order to determine viability (AnnexinV-/PI-) of T cells during the ex vivo expansion 
flow cytometry analysis was performed. High viabilities for CD8+ and CD4+ T cells 
were detected prior to expansion (Figure 4, upper panel) or following a 7-day 
expansion (Figure 4. lower panel).  
In order to determine phenotype distribution of T cells and the effects that ex vivo 
expansion may have on the differentiation of T cells, we performed flow cytometry 
analyses. Freshly isolated CD8+ T cells contained mainly central/memory and naïve 
phenotypes accounting for 51.43% of central/memory (TCM: CD44+CD62Lhigh) and 
30.71% of naïve (TN: CD44-CD62L+) T cells as well as 7.52% of effector phenotype 
(TE: CD44+CD62L-) and 9.52% of effector/memory phenotypes (TEM: 
CD44+CD62Llow). Freshly isolated CD4+ T cells contained mainly central/memory and 
effector phenotypes accounting for 57.85% of TCM and 29.03% of TE cells as well as 
8.08% of TEM and 5.61% of TN cells (Figure 5, upper panel). Ex vivo expansion with 
the alternating gamma chain cytokines generated increased TE phenotypes for CD8+ 
(16.76%) and CD4+ (36.86%) T cells (Figure 5, lower panel). However, TCM remained 
the most abundant phenotypes after the ex vivo expansion of CD8+ and CD4+ T cells 
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(Figure 5, lower panel).  The MFI for CD44 expression in the expanded CD8+ and 
CD4+ T cells were 5.61 and 7.28, respectively. 
In order to determine whether the ex vivo expansion of T cells may enrich for the tumor-
reactive T cells, we determined production of IFN-γ and cytotoxic function of T cells in 
the presence (+) and absence (-) of MMC tumor cells at an effector:target (E:T) ratio of 
10:1. Supernatants were collected after a 24-hour culture and assayed for IFN-γ by 
ELISA. Figure 6 shows that freshly isolated splenocytes produced IFN-γ when 
stimulated with irradiated MMC in vitro (3580.5 pg/ml; p= 0.0000005). Importantly, 
the ex vivo expanded T cells showed significantly higher production of tumor-induced 
IFN-γ than freshly isolated T cells (8.2 fold; 29400 pg/ml p = 0.036).   
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Figure 4:  Ex vivo expansion of T cells with the alternating gamma chain cytokine 
formulation supports maintenance of highly viable lymphocyte population 
Spleen harvested from MMC sensitized large tumor-bearing (tumor volume≤2000mm³) 
female FVBN202 mouse was crushed and processed to yield single cell suspensions 
which were subjected to a 7-day expansion with alternating gamma chain cytokines. 
The cells were gated on CD8+ or CD4+ cells and analyzed for AnnexinV and PI. 
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Figure 5: Ex vivo expansion of T cells with the alternating gamma chain cytokines 
supports effector (TE) and central/memory (TCM) T cell phenotypes 
Spleen harvested from MMC sensitized large tumor-bearing (tumor volume≤2000mm³) 
female FVBN202 mouse was crushed and processed to yield single cell suspensions 
which were subjected to a 7-day expansion with alternating gamma chain cytokines. 
The ex vivo expanded and freshly isolated T cells were stained with CD62L, CD44 and 
CD8/CD4 antibodies. Gated CD8+ and CD4+ T cells were analyzed within 50,000 
viable cells for the expression of CD44 and CD62L. The CD44+CD62L- (TE), CD44+ 
CD62Llow (TEM), CD44+CD62Lhigh (TCM) and CD44-CD62L+ (TN) phenotypes are 
shown. 
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Figure 6:  Ex vivo expanded T cells with the alternating gamma chain cytokines 
produce more IFN-γ than freshly isolated T cells upon in vitro stimulation with neu 
positive MMC 
The ex vivo expanded and freshly isolated T cells were cultured either alone or with 
irradiated neu+ MMC (15000 rad) in the effector:target ratio of 10:1 for 24 hours and 
supernatants were tested for IFN-γ secretion by using ELISA. 
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To confirm the anti-tumor efficacy in vitro, T cells were co-cultured with viable MMC 
target cells (E:T ratio of 10:1) for 48 hours followed by staining with antibodies 
directed towards neu, Annexin V and PI. Control wells were seeded with MMC in the 
absence of T cells. Gated neu positive MMC cells were analyzed for Annexin V and PI 
to determine apoptosis of tumor cells by freshly isolated as well as the ex vivo expanded 
T cells. Figure 7 shows that viability (Annexin V-/PI-) of MMC decreased from 
92.26% in the absence of T cells to 68.57% and to 61.69% in the presence of freshly 
isolated and the ex vivo expanded T cells, respectively.  
To test the anti-tumor response potential in vivo, the ex vivo expanded T cells were used 
for AIT in FVBN202 mice challenged with neu positive MMC. Prior to transfer of the 
ex vivo expanded T cells, animals were treated with Cyclophosphamide (CYP) for 
lymphodepletion. Control mouse did not receive AIT. Figure 8 shows the failure of T 
cells expanded with the alternating gamma chain cytokines to induce tumor rejection.  
Since the alternating common gamma chain cytokine formulation could not support the 
expansion of T cells that could cause tumor regression in FVBN202 mice, we came up 
with the sequential common gamma chain cytokine regimen for the ex vivo expansion 
of T cells. We hypothesized that continuation of T cell culture with IL-2 following 
initial culture with IL-7 + IL-15 could support the expansion of CD8+ TE cells that, 
compared to naïve or central/memory T cells, may be refractory to MDSCs and result in 
tumor rejection upon AIT even in the presence of endogenous MDSCs.  
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Figure 7:  Ex vivo expanded T cells with the alternating gamma chain cytokines 
did not show an enhanced anti-tumor efficacy compared to the freshly isolated T 
cells 
The freshly isolated and ex vivo expanded T cells were cultured with neu positive MMC 
in an effector:target ratio of 10:1, the control wells were seeded with MMC alone and 
cultured for 48 hours. The cells were stained with antibodies against neu, AnnexinV and 
PI. Gated neu+ population were analyzed for Annexin V and PI.  
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Figure 8: AIT by using T cells expanded with the alternating gamma chain 
cytokines fail to cause tumor regression in vivo 
FVBN202 mice were inoculated with MMC (3 million per mouse) and then injected i.v. 
with 70 million of the ex vivo expanded T cells. Prior to AIT, mice received CYP 
treatment to cause lymphodepletion. Control mice received CYP treatment and MMC 
challenge but no AIT. The tumor growth was presented as volume.  
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Results 
Experimental designs 
In order to improve anti-tumor efficacy of AIT we made two modifications in our 
protocol. First, we decided to collect T cells from FVBN202 donors early during tumor 
development when tumor volume was 200-400 mm3 rather than late during tumor 
burden when tumor volume reached 2000 mm3. Secondly, we changed the alternating 
gamma chain cytokine formulation to a sequential cytokine formulation (IL-7+ IL-15 
followed by IL-2). Since IL-2 can cause activation-induced cell death (AICD), T cells at 
late stage of differentiation would die and those at early stage of differentiation would 
survive. This could enrich for effector and effector/memory phenotypes that may last 
longer in vivo.  Figure 9 shows the schematic representation of the experimental 
procedures. Spleens were harvested from MMC-sensitized tumor-bearing female 
FVBN202 mice, crushed and processed to obtain single cell suspension. Freshly 
isolated splenocytes were used for functional assay, in vitro anti-tumor responses, and 
phenotype analysis as well as the ex vivo expansion. Splenocytes were stimulated with 
Bryostatin-1/Ionomycin (B/I) + IL-2 (80 U/106 cells/ml) for 16 hours followed by an 
initial culture with IL-7+IL-15 (10-20 ng/106 cells/ml) for 24 hours then pulsed with IL-
2 (20U/106 cells/ml). One day after, cells were split and cultured with IL-2 (40U/106 
cells/ml) for the next 3-4 days. The ex vivo expanded T cells were used for in vitro 
assays and AIT by i.v. route (7 x 107 cells/mouse). The recipients of AIT received 
cyclophosphamide (100mg/Kg) 24 hours prior to AIT and were subjected to MMC 
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challenge a few hours before AIT. Twenty three days after, when animals had rejected 
primary tumors, they were further challenged with MMC without any 
cyclophosphamide in order to determine memory responses. On days 50 and 61 
following primary tumor challenge, animals were challenged with ANV and MMC, 
respectively. While one group received ANV on the contralateral side and MMC on the 
same side, another group was challenged with ANV on the contralateral side only. 
Naïve mice challenged with the tumor served as control. Animals were then sacrificed 
and their T cells were analyzed in vitro. 
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Figure 9: Schematic representation of the experimental design 
Spleens were harvested from MMC-sensitized tumor-bearing (either bearing small or 
large tumors) female FVBN202 mice, crushed and processed to obtain single cell 
suspension. Freshly isolated splenocytes were used for functional assay, in vitro anti-
tumor responses, and phenotype analysis as well as ex vivo expansion with sequential 
common gamma chain cytokine formulation for AIT. Twenty three days after AIT, 
when animals had rejected MMC tumors, they were further challenged with MMC 
without any cyclophosphamide in order to determine memory responses. On days 50 
and 61 following primary tumor challenge, animals were challenged with ANV on the 
contralateral side and/or with MMC, respectively. While one group received ANV on 
the contralateral side and MMC on the same side, another group was challenged with 
ANV on the contralateral side only. Naïve mice challenged with the tumor served as 
control. 71- 80 days after the primary tumor challenge animals were sacrificed and their 
splenic T cells were subjected to in vitro analyses. 
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Sequential common gamma-chain cytokines expand T cells, preferentially CD4+ T 
cells, from FVBN202 donor mice bearing small tumors 
Spleens were harvested from FVBN202 donors 10-14 days after MMC challenge, when 
tumor volume was between 150mm³-300mm³. These tumor-sensitized T cells were 
nurtured and proliferated in the presence of sequential gamma chain cytokines and 
exhibited high anti-tumor efficacy. We first determined the level of MDSCs in the 
spleen of donor mice. Figure 10A shows that MDSCs accounted for 17.91% gated and 
6.25% total splenocytes. Figure 10B shows two major subsets of MDSCs. 
Ly6C+Ly6G-  subsets accounted for 18.44% on gated CD11b+ and 0.68% of total 
splenic cells while Ly6C+Ly6G+ subsets accounted for 69.51% gated CD11b+ and 
2.1% of total splenic cells. Prior to, during and after the ex vivo expansion of 
splenocytes, trypan blue exclusion was performed to determine the fold expansion. 
Figure 11 shows the fold expansion of splenocytes that was comparable to that of the 
alternating gamma chain cytokines (Figure 2). There was about 2.9 fold reduction after 
B/I stimulation compared to day 0 baseline. On day three, five and six, number of cells 
increased consistently, ultimately expanding up to 1.9 and 6.5 fold on day 6 compared 
to day 0 and post-B/I activation. We then performed flow cytometry analysis of T cell 
subsets to determine their relative proportions. All gated CD4+ or CD8+ cells were 
found to be CD3+ which proves they were bona fide T cells (Figure 12, lower panel). 
Both CD8+ and CD4+ T cells were expanded in the presence of the sequential gamma 
chain cytokines (Figure 13). Rate of expansion was relatively lower than when the 
alternative gamma chain cytokines was used (Figure 3). Unlike the alternating common 
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gamma chain cytokines, the sequential cytokines preferentially expanded CD4+ T cells 
(Figures 3 and 13) such that the proportion of CD4+ T cells was higher than CD8+ T 
cells after the expansion. 
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Figure10:  FVBN202 donor mice bearing small tumors have a moderate level of 
endogenous splenic MDSCs 
Spleens harvested from MMC-sensitized tumor bearing (tumor volume=150-300mm³) 
female FVBN202 mice were stained with antibodies against CD11b, Ly6G, and Gr1 
(Ly6C). A total of 100,000 cells were analyzed by flow cytometry to examine the level 
of endogenous MDSCs and its monocytic and granulocytic subpopulation. (A) percent 
total and percent gated population of CD11b+Gr1+ (upper right quadrant) MDSCs. (B) 
percent gated and percent total population of CD11b+Gr1+ subsets. The Ly6C+Ly6G- 
(upper left quadrant) shows the suppressive monocytic subpopulation whereas the 
Ly6C+Ly6G+ (upper right quadrant) depicts non-suppressive subpopulation. The bar 
graphs with error bars show the average values from three different mice±SD. 
59 
 
 
Figure 10 
 
 
 
 
 
 
 
 
 
 
 
 
60 
 
Figure 11: Ex vivo expansion of splenocytes with sequential (IL-7/IL-15→IL-2) 
gamma chain cytokines  
Spleens harvested from MMC-sensitized tumor bearing (tumor volume=150-300mm³) 
female FVBN202 mice (n=2) were crushed and processed to yield single cell 
suspensions which were subjected to 6 day expansion with sequential common gamma 
chain cytokines. T cells were incubated with 5nM Bryostatin-1 and 10nM Ionomycin 
along with 80 U/ml of IL-2 in complete medium for 16 hours followed by expansion 
with IL-7/IL-15 (10ng/ml), and then with IL-2 (40U/ml). Cell counts were performed 
using trypan blue exclusion. 
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Figure 12: The sequential common gamma chain cytokine formulation 
preferentially expands CD3+ T cells 
The ex vivo expanded T cells were stained with CD8, CD3 and CD4 antibodies and 
100,000 viable cells from each sample were analyzed by flow cytometry to examine the 
percentage of CD3+ cell among the expanded population. Gated CD8+ or CD4+ cells 
were then analyzed for the expression of CD3.  
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Figure 13: Expansion of splenocytes with the sequential common gamma chain 
cytokines results in the expansion of CD8+ and CD4+ T cells 
Splenocytes were stained with antibodies towards CD8 and CD4 prior to and after a 6-
day expansion. Percent total of gated CD8+ and CD4+ T cells were determined. 
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The ex vivo expanded T cells show reduced viability 
The success of adoptive immunotherapy depends on viability of the ex vivo expanded T 
cells. First, in order to determine whether MMC stimulation may affect viability of T 
cells, freshly isolated splenocytes were cultured in the presence or absence of MMC for 
24 hours. As shown in Figure 14, Annexin V- viable T cells did not change 
dramatically after the stimulation with MMC (p > 0.2). Viability of freshly isolated 
CD8+ T cells was 61.67% of which CD8high T cells had higher viability than CD8low T 
cells (Figure 14A; 72.05% vs. 14.13%, p =0.0000031). Because of a 24 hour culture of 
the freshly isolated T cells there was a reduction in viability which made it impossible 
to compare it with the viability of T cells after the ex vivo expansion. However, we 
know that viability of the freshly isolated T cells is above 87% (Figure 4). Considering 
that expansion of T cells with the sequential common gamma chain cytokines resulted 
in a reduced viability of CD8+ and CD4+ T cells (Figure 14B) compared to T cells 
expanded with the alternating common gamma chain cytokines (Figure 4). 
Ex vivo expanded T cells with the sequential common gamma chain cytokines show 
an increased tumor-specific IFN-γ production in vitro 
In order to determine whether T cells expanded with the sequential common gamma 
chain cytokines were enriched for tumor-reactive phenotypes, we performed in vitro 
assays. Freshly isolated T cells or ex vivo expanded T cells were cultured either with (+) 
or without irradiated MMC (-) for 24 hours and then analyzed for their activation. 
Figure 15A shows negligible production of MMC-induced IFN-γ by freshly isolated T 
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cells whereas the ex vivo expanded T cells produced significant amounts of IFN-γ upon 
stimulation with MMC (p=0.002), as determined by IFN-γ ELISA. In order to 
determine the cellular source of the IFN-γ production, flow cytometry analyses were 
performed. Figure 15B shows a 5.3 fold higher proportion of CD8+ IFN-γ+ T cells 
upon MMC stimulation (from 1.23% to 6.53%, p=0.04) whereas CD4+ T cells did not 
show any significant increase in IFN-γ production (p=0.18). Increased IFN-γ production 
were noticeable in both CD8high (p=0.042) and CD8low (p=0.037) T cells.  
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Figure 14: Viability of freshly isolated and ex vivo expanded T cells 
The lymphocytes were harvested from MMC-sensitized small tumor-bearing (tumor 
size=150-300 mm³) female FVBN202 mice and subjected to 6 day expansion with the 
sequential common gamma chain cytokines. Freshly harvested lymphocytes were 
cultured alone or with irradiated MMC in the effector:target ratio of 10:1 for 24 hours 
and stained with antibodies towards CD8, CD4 and AnnexinV. The ex vivo expanded T 
cells were cultured alone and stained similarly. The upper left quadrants representing 
CD8+AnnexinV-/CD4+AnnexinV- are considered to be viable.  The middle panel 
shows the gating pattern, how CD8 high and low population was separated. 
Representative dot plots (A) as well as average of the means for two separate 
experiments (B) are shown. 
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Figure 15: T cells expanded with the sequential common gamma chain cytokine 
formulation can produce more IFN-γ than freshly isolated T cells upon in vitro 
stimulation with MMC tumor cells 
Freshly isolated and ex vivo expanded T cells were either cultured alone or with 
irradiated MMC in an effector:target ratio of 10:1 for 24 hours and supernatants were 
tested for IFN-γ secretion. (A) data from IFN-γ ELISA, representing IFN-γ secretion by 
freshly isolated (left panel) and ex vivo expanded (right panel) T cells with and without 
MMC stimulation. (B) represents dot plots from flow cytometric analyses of IFN-γ 
staining for CD8+ and CD4+ T cells. A total of 100,000 cells of each sample was 
analyzed. The bar graph with error bars represents the average of percent gated 
population of IFN-γ+CD8+, IFN-γ+CD8high+, IFN-γ+CD8low+, IFN-γ+CD4+ 
populations from two different experiments. 
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Ex vivo expanded T cells with the sequential common gamma chain cytokines show 
an increased tumor-specific perforin (Prf) production as well as granzyme B (GrB) 
and CD69 expression in vitro 
Perforin (Prf) is a cytotoxic protein aids in delivering contents of granules into the 
cytoplasm of target cells. These granules can cause apoptosis of the target cells. The 
increased production of Prf by T lymphocytes can be considered as “marker” of 
cytotoxic potential of T cells. Therefore, we looked at the ability of T cells to produce 
Prf in tumor-specific fashion. Freshly isolated CD4+ T cells were found to have marked 
increase in the number of cells producing perforin (Prf) upon MMC stimulation (0.63% 
vs. 2.98%, p=0.02) whereas CD8+ T cells did not show any appreciable changes (1.49% 
vs. 2.94, p=0.3) (Figure 16). The ex vivo expanded T cells did not show any marked 
increase in Prf production upon MMC stimulation (Figure 17). However, compared to 
freshly isolated T cells, only marginal increase in Prf production was detected in the ex 
vivo expanded CD8+ T cells (Figures 16 and 17; 1.49% vs. 2.74%, p=0.17). 
Granzyme-B is a serine protease which activates apoptosis once within the target cells. 
Both CD4+ and CD8+ T cells, either freshly isolated (Figure 18) or ex vivo expanded 
(Figure 19), showed high expression of GrB (> 90%) and it did not increase upon 
MMC stimulation in vitro.  
The early activation marker, CD69, showed a 2.82 fold increase in freshly isolated 
CD8+ T cells (10.23% vs. 28.86%, p=0.002) and a 1.99 fold increase on CD4+ T cells 
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(19.13% vs. 38.19%, p=0.001) when stimulated with MMC (Figure 20). Importantly, 
the ex vivo expanded CD8+ T cells showed significantly higher expression of CD69 
compared to freshly isolated ones (Figures 20 and 21; 10.23% vs. 81.06%, p=0.04) 
whereas no increases were detected on CD4+ T cells following the ex vivo expansion 
(Figures 20 and 21; 19.13% vs. 14.85%, p=0.16).  These ex vivo expanded CD8+ T 
cells and CD4+ T cells showed no significant increase in CD69 expression upon MMC 
stimulation in vitro (Figure 21, CD8+ T cells: 81.06 vs. 84.41%, CD4+ T cells: 14.85% 
vs. 18.87%, p=0.2). 
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Figure 16: Freshly isolated CD4+ T cells show increased production of Prf upon in 
vitro stimulation with MMC  
Splenocytes of FVBN202 donors bearing small tumors were stained with CD8, CD4 
and Prf antibodies before and after a 24-hour stimulation with irradiated MMC. A total 
of 100,000 cells per sample were analyzed to detect the production of Prf. Gated CD8+ 
and CD4+ T cells were analyzed for the detection of Prf. The bar graphs with error bars 
represent the average values from three different animals. 
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Figure 17: T cells expanded with the sequential common gamma chain cytokine 
formulation show higher basal level of endogenous perforin (Prf) than freshly 
isolated T cells but fail to increase Prf upon MMC stimulation 
Splenocytes harvested from MMC-sensitized small tumor-bearing female FVBN202 
mice were subjected to 6 day expansion with the sequential common gamma chain 
cytokines and were stained with CD8, CD4 and Prf antibodies before and after 
stimulation with MMC. A total of 100,000 cells per sample were analyzed by flow 
cytometry. Gated CD8+ and CD4+ cells were analyzed for the expression of Prf. The 
bar graph with error bars represents the average values of two different experiments. 
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Figure 18: Freshly isolated T cells show high level of granzyme-B (GrB) 
production 
A total of 100,000 cells per sample were analyzed to detect the production of GrB on 
gated CD8+ and CD4+ cells before and after MMC stimulation. The bar graphs with 
error bars represent the average values from three different animals examined separately 
in a single experiment. 
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Figure 19: T cells expanded with the sequential common gamma chain cytokine 
formulation show high level of granzyme B (GrB) 
A total of 100,000 cells per sample were analyzed to detect the production of GrB on 
gated CD8+ and CD4+ cells before and after MMC stimulation. The bar graphs with 
error bars represent the average values from three different animals examined separately 
in a single experiment. 
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Figure 20: The CD8+ and CD4+ T lymphocytes harvested freshly from MMC-
sensitized small tumor-bearing (tumor volume=150-300mm³) female FVBN202 
mice show significant expression of CD69 on MMC stimulation 
A total of 100,000 cells per sample were analyzed to detect the expression of CD69 on 
gated CD8+ and CD4+ cells before and after MMC stimulation. The bar graphs with 
error bars represent the average values from three different animals examined separately 
in a single experiment. 
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Figure 21: The ex vivo expanded T cells with the sequential common  gamma chain 
cytokines show an increased basal level of CD69 expression even in the absence of 
MMC stimulation in vitro 
A total of 100,000 cells per sample were analyzed to detect the expression of CD69 on 
gated CD8+ and CD4+ cells before and after MMC stimulation. The bar graphs with 
error bars represent the average values from three different animals examined separately 
in a single experiment. 
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T cells expanded with the sequential common gamma chain cytokines are highly 
effective against the tumor and are refractory to MDSCs in vivo 
In order to determine whether the ex vivo-expanded tumor-reactive T cells may also 
protect FVBN202 mice against tumor challenge even in the presence of endogenous 
MDSCs, AIT was performed. FVBN202 mice were challenged with MMC 24 hours 
after cyclophosphamide injection. Animals were split into two groups; the control group 
remained untreated whereas the test group was subjected to AIT in the absence of 
MDSC depletion in vivo. Figure 22 shows complete rejection of the tumor following 
AIT. The control mice (without AIT) developed tumors, as expected.  
In order to determine the phenotype distribution of T cells, flow cytometry analyses 
were performed. Figure 23 shows the phenotypic distribution of CD8+ and CD4+ T 
cells in the freshly isolated splenocytes. TCM and TN phenotypes were the most abundant 
cells for both CD8+ and CD4+ T cells. CD8+ T cells consisted of 5.62% effector (TE), 
9.91% of effector memory (TEM), 57.23% central memory (TCM) and 26.28% of naïve 
(TN) phenotypes.  The CD4+ T cells were of 7.97% effector, 7.77% effectors memory, 
59.98% central memory and 22.61% of naïve phenotypes. Phenotypic distribution of the 
ex vivo expanded T cells is shown in Figure 24. The ex vivo expanded CD8+ T cells 
showed marked increases in TE and TEM phenotypes whereas CD4+ T cells showed an 
increased TE and TCM phenotypes compared to the freshly isolated T cells (Figures 23 
and 24). The ex vivo expanded CD8+ T cells consisted of 43.90% effector, 16.40% 
effectors memory, 36.43% central memory, and 1.75% naïve phenotypes. The CD4+ T 
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cells were of 26.33% effector, 9.58% effector memory, 61.27% central memory, and 
1.95% naïve phenotypes.  
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Figure 22: T cells expanded with the sequential common gamma chain cytokines 
are highly effective against the tumor and are refractory to MDSCs in vivo 
The ex vivo expanded T cells were used for AIT in FVBN202 mice (n=3) challenged 
with 3 million MMC. Mice were treated with CYP for lymphodepletion. The control 
mice (n=2) received CYP treatment and MMC challenge but no AIT. The figure shows 
the tumor growth pattern of the control (upper panel) and the recipient of AIT (lower 
panel).  
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Figure 23: Phenotypic distribution of freshly isolated T cells harvested from 
MMC-sensitized small tumor-bearing FVBN202 mice  
The freshly isolated T cells were stained with CD44, CD62L and CD8/CD4 antibodies 
and fluorescence of 100,000 viable cells were analyzed by flow cytometry. The lowest 
panel is a representative dot plot with the quadrants marked for the distribution of 
various phenotypic subsets of T cells. The upper left panel represents the auto 
fluorescence of the sample and the fluorescence for single colored antibodies. The 
upper middle panel shows the phenotypic distribution of the CD8+ and CD4+ T cells. 
The bar graphs with error bars (upper right panel) represent the average of 3 different 
animals examined in a single experiment. 
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Compared to freshly isolated CD8+ T cells, the ex vivo expanded cells showed a 
marked shift toward effector cells (Figures 23 and 24; 5.62% vs. 43.9%, p=0.02) and 
effector/memory cells (9.91% vs.16.4%, p=0.004) whereas central/memory cells 
decreased from 57.23% to 36.4% (p=0.006). A marked decrease was also observed in 
naïve CD8+ T cells (26.28% vs. 1.7%, p=0.0001). The MFI for CD44 expression in 
CD8+ T cells was 85.2 which were over 14 fold higher than that expressed in T cells 
expanded with the alternating gamma chain cytokines (Figure 5). Compared to freshly 
isolated CD4+ T cells, the ex vivo expanded CD4+ T cells showed an increase in 
effector phenotypes (7.97% vs. 26.33%, p=0.1) while no changes were observed in 
effector/memory (7.77% vs. 9.58%, p=0.28) and central/memory (59.98% vs. 61.27%, 
p=0.42) phenotypes. Naïve CD8+ T cells showed a marked decrease following the ex 
vivo expansion (22.61% vs. 1.95%, p=0.001). The MFI for CD44 expression in CD4+ T 
cells was 51.5 which was 8-10 fold higher than that expressed in T cells expanded with 
the alternating gamma chain cytokines (Figure 5).  
Sequential common gamma chain cytokines support the proliferation and 
differentiation of T cells that are highly effective against the tumor and are 
refractory to MDSCs in vitro 
Since the ex vivo-expanded T cells with the sequential common gamma chain cytokines 
showed an increased tumor-reactivity in vitro evidenced by the production of IFN-γ and 
CD69 expression as well as an anti-tumor efficacy in vivo, we sought 
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to determine whether the expanded T cells would show an enhanced cytotoxicity 
against the tumor cells in vitro. Freshly isolated or ex vivo expanded T cells were co-
cultured with MMC target cells (E:T ratio of 10:1) for 48 hours followed by staining 
with antibodies directed towards neu, Annexin V and PI. Control wells were seeded 
with MMC in the absence of T cells. Gated neu positive cells were then analyzed to 
detect apoptosis (AnnexinV+ and PI+ cells). Figure 25 shows the result of cytotoxicity 
assays in vitro. The control MMC cells in the absence of T cells showed 87.50% 
viability (AnnexinV-/PI-). Viability of MMC dropped to 50.79% in the presence of 
freshly isolated T cells. When co-cultured with the ex vivo expanded T cells the 
viability of MMC dropped from 68.8% to 17.6% (p=0.000027). By normalizing the 
viability of control MMC to 100%, the ex vivo expanded T cells were found to be more 
efficient in inducing apoptosis of tumor cells than freshly isolated T cells. 
Since AIT with the ex vivo expanded T cells using sequential gamma chain cytokines 
but not alternating gamma chain cytokines induced tumor rejection, even in the absence 
of MDSC depletion in vivo, we hypothesized that the sequential gamma chain cytokine 
regimen supported proliferation and differentiation of T cells that are refractory to the 
inhibitory effects of MDSCs. In order to test this, T cells were co-cultured with MMC 
in the presence or absence of MDSCs in vitro. Figure 26A shows that the ex vivo 
expanded T cells produced a significantly more IFN-γ in the presence of irradiated 
MMC when compared with T cells alone (T vs. T+MMC p=0.035). In addition, 
presence of MDSCs at 2:1 ratio (T: MDSCs) did not inhibit MMC-specific IFN-γ 
production, with a marginal increase in the level of IFN-γ (p= 0.09). No significant 
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secretion of IFN-γ was detected in MMC, MDSCs or T cells alone. To determine 
cellular source of IFN-γ production we performed flow cytometry analyses. The gating 
patterns used for the analyses are shown in Figure 26B; the lymphocyte region was first 
gated and CD8+ T cells and CD4+ T cells were re-gated out in order to determine IFN-γ 
production by the T cell subsets. Figure 26C shows that the ex vivo expanded CD8+ T 
cells produced IFN-γ when stimulated with MMC in the absence or presence of MDSCs 
(0.75% vs. 11.67% or vs. 30.04%).  The CD4+ T cells also showed increased IFN-γ 
production upon MMC stimulation in the absence or presence of MDSCs (0.29% 
vs.3.24% or vs.11.23%). There were significant increases in IFN-γ production by CD8+ 
(p=0.04), CD8high (p=0.04) and CD8low (p=0.037) T cells upon MMC stimulation 
whereas CD4+ T cells showed a negligible increase (p=0.18) in IFN-γ production.  
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Figure 24: Phenotypic distribution of the T cells harvested from MMC-sensitized 
small tumor-bearing FVBN202 mice and expanded with the sequential common 
gamma chain cytokines 
T cells were stained with CD44, CD62L and CD8/CD4 antibodies and fluorescence of 
100,000 viable cells were analyzed by flow cytometry. The far left panel represents the 
auto fluorescence of the sample and the fluorescence for single colored antibodies. The 
middle panel shows the phenotypic distribution of the CD8+ and CD4+ T cells. The bar 
graphs with error bars (right panel) represent the average values of two different 
experiments. 
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Figure 25: T cells expanded with the sequential gamma chain cytokines show  
more anti-tumor efficacy than freshly isolated lymphocytes 
The cells were stained with antibodies against neu, AnnexinV and PI. The neu+ cells 
were gated and viability was determined. The lower left panel represents the viable 
population (AnnexinV- PI-). The figure shows the viability of MMC control and MMC 
cultured with freshly isolated lymphocytes(upper panel) and MMC control and MMC 
cultured with ex vivo expanded T cells (lower panel). In the bar graph the viability of 
control MMC has been normalized to 100%. The bar graph (above) represents the 
average of 3 animals and the bar graph (below) shows the average values from 2 
different experiments. 
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 Figure 26: T cells expanded with sequential common gamma chain cytokines 
produce tumor-specific IFN-γ even in the presence of MDSCs  
            The T cells expanded ex vivo with sequential common gamma chain cytokines were 
cultured alone, with irradiated MMC and together with irradiated MMC and MDSC in 
the Effector:Target:MDSC ratio of  10:1:5 for 24 hours and the supernatants were tested 
for the level of secreted IFN-γ. (A) represents data of IFN-γ ELISA and shows that T 
cells can produce more IFN-γ on stimulation with MMC even in presence of MDSC. 
The error bars show the average values from two different experiments. (B) represents 
the gating pattern followed to gate out the CD8+ and CD4+ T cells during flow 
cytometry analyses, in order to confirm that the potential source of IFN-γ is the T 
lymphocytes but not the MDSC. (C) ex vivo expanded T cells were stained with the 
CD8, CD4 and IFN-γ antibodies and flow cytometry analyses were done. The upper 
panel shows the amount of IFN-γ produced by T cells alone and by T cells on MMC 
stimulation. The middle panel represents the histogram showing that the contribution of 
MMC in IFN-γ production was negligible, and the lower panel shows the level of IFN-γ 
secreted by cells when cocultured with MDSCs. The bar graph with error bars 
represents the average values from two different experiments. 
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Figure 27: T cells expanded with the sequential common gamma chain cytokines 
are refractory to the inhibitory effects of MDSCs and can produce perforin (Prf) 
upon MMC stimulation even in presence of MDSCs   
            The T cells expanded ex vivo with sequential common gamma chain cytokines were 
cultured alone, with irradiated MMC and together with irradiated MMC and MDSC in 
the Effector:Target:MDSC ratio of 10:1:5 for 24 hours and the supernatants were tested 
for the level of Prf. The ex vivo expanded T cells were stained with CD8, CD4 and Prf 
antibodies and flow cytometry analyses were done. The upper panel shows the amount 
of Prf produced by T cells alone and by T cells on MMC stimulation. The middle panel 
represents the histogram showing the contribution of MMC in Prf production was 
negligible, and the lower panel shows the level of IFN-γ secreted by cells when 
cocultured with MDSCs. The bar graph with error bars represents the average values 
from two different experiments. 
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Presence of MDSCs slightly increased IFN-γ production by CD8+ T cells upon MMC 
stimulation, though it was not found to be significant (p=0.09). A similar trend as to the 
effects of MDSCs on T cell responses was detected for perforin production by the ex 
vivo expanded T cells (Figure 27). Initially 8.62% of CD8+T cells were found to be 
positive for perforin, the percentage increased slightly to 10.12% and further to 32.34% 
when co-cultured with MMC alone and MMC+MDSC, respectively. The percentage of 
CD4+ Prf+ T cells increased from 2.37% to 7.24% with MMC alone and further to 
11.07% with MMC + MDSCs. Although there was increased perforin production by T 
cells stimulated with MMC in presence or absence of MDSCs, the statistical analyses of 
the repeat experiments revealed no significant differences (for CD8+ cells; T vs. 
T+MMC  p=0.28; T vs. T+MMC+MDSC  p= 0.14). 
Figures 28 and 29 show that addition of MDSCs did not alter the Granzyme-B 
production nor did alter the expression of CD69.  
Finally, in vitro cytotoxicity assays revealed that the ex vivo expanded T cells can kill 
MMC even in the presence of MDSCs (Figure 30). Neu positive MMC target cells 
were co-cultured with the ex vivo expanded T cells in the presence or absence of 
MDSCs (E:T:MDSC ratios of 10:1:5) for 48 hours followed by staining with antibodies 
directed towards neu, Annexin V and PI. Control wells were seeded with MMC in the 
absence of T cells. Gated neu positive cells showed apoptosis in the presence of T cells 
regardless of the presence or absence of MDSCs.  Viability of MMC dropped from 
74.87% to 3.66% (p= 0.004) when co-cultured with T cells and was further reduced to 
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1.22% (p =0.003) in the presence of MDSCs. There were no significant differences in 
the apoptosis of MMC induced by T cells in the presence or absence of MDSCs (p= 
0.3). 
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Figure 28: T cells expanded with the sequential common gamma chain cytokines 
are refractory to the inhibitory effects of MDSCs and can maintain unaltered 
Granzyme-B (GrB) upon MMC stimulation and in the presence of MDSC 
            The ex vivo expanded T cells were stained with the CD8, CD4 and GrB antibodies and 
flow cytometry analyses were done. The upper panel shows the amount of GrB 
produced by T cells alone and by T cells upon MMC stimulation and the lower panel 
shows the level of GrB secreted by cells when co-cultured with MDSCs. There is no 
increase in GrB production upon MMC stimulation as the endogenous level has reached 
saturation. 
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Figure 29: T cells expanded with the sequential common gamma chain cytokines 
are refractory to the inhibitory effects of MDSCs and can maintain unaltered 
expression of CD69 upon MMC stimulation even in presence of MDSCs 
            The ex vivo expanded T cells were stained with the CD8, CD4 and CD69 antibodies and 
flow cytometry analyses were done. The upper panel shows the amount of CD69 
expressed by T cells alone and by T cells upon MMC stimulation and the lower panel 
shows the level of CD69 expression by cells when co-cultured with MDSCs. There is 
no marked increase in CD69 expression as the endogenous level has reached saturation. 
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Figure 30: T cells expanded with the sequential common gamma chain cytokines 
show an enhanced cytotoxicity against MMC compared to freshly isolated T cells 
even in the presence of MDSCs 
The freshly isolated and the ex vivo expanded T cells were cultured with MMC or with 
MMC and MDSC in the Effector: Target:MDSC ratio of 10:1:5. The control wells were 
seeded with MMC alone and cultured for 48 hours. The cells were stained with neu, 
AnnexinV and PI antibodies. The neu+ cells were gated and viability was determined. 
In the bar graph the viability of control MMC has been normalized to 100%. The dot 
plots represent the viability of the control MMC and MMC co-cultured with T cells and 
MDSCs. The bar graph shows the average values from 2 different experiments. 
114 
 
 
Figure 30 
 
 
 
115 
 
Sequential common gamma chain cytokines expand tumor-reactive T cells derived 
from the FVBN202 donors bearing large tumors 
Since donors of T cells that were expanded with the alternating gamma chain cytokines 
were harboring large tumors whereas those expanded with the sequential gamma chain 
cytokines had small tumors, we sought to determine whether the source of T cells 
during early versus late tumorigenesis may be responsible for the differential effects 
that we observed. In order to test this possibility, we collected T cells from FVBN202 
donors carrying large tumors (>1000 mm3) and expanded them with sequential gamma 
chain cytokines followed by in vitro and in vivo analyses. Figure 31 shows the level of 
MDSCs in the spleen of donors, accounting for 73.4% of the granulocyte gated and 
9.3% of the total splenocytes. Spleens from two donors were harvested 21 days after 
MMC challenge, pooled together, and subjected to a 6-day expansion with the 
sequential gamma chain cytokines. Figure 32 shows a drop from 150 million cells to 
77.7 million cells after the B/I activation followed by the expansion to 805.98 million 
cells on day six. There was 5.37 and 10.36 fold increase of T lymphocytes compared to 
day 0 and post B/I activation respectively. T cells expanded with the sequential 
common gamma chain cytokines showed better expansion potential than with those 
expanded with the alternating gamma chain cytokine regimen. Figure 33 shows that the 
ex vivo expanded CD8+ T cells increased from 4.06% to 25.88% (6.37 fold) and CD4+ 
T cells increased from 12.15% to 46.78% (3.85 fold). The expanded T cells were used 
for further in vitro experiments to assess the anti-tumor responses. Figure 34A shows a 
marked increase in IFN-γ production by the ex vivo expanded T cells stimulated with 
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MMC (CD8+ T cells: 5% vs. 30%; CD4+ T cells: 0.1% vs. 1%). A similar trend was 
detected when T cells were analyzed for the expression of perforin (Figure 34B). 
CD8+Prf+ T cells were increased from 58% to 84% and CD4+Prf+ T cells were 
increased from 7% to 16.4%, when stimulated with MMC in vitro. Compared to the 
expanded T cells derived from donors bearing small tumors (Figure 17), those from 
donors with large tumors (Figure 34B) showed increase in CD8+Prf+ T cells in the 
absence (2.74% vs. 58%) or presence of MMC (6.15% vs. 84%). Similar trends were 
detected for CD4+Prf+ T cells in the absence (1.1% vs. 7%) or presence (0.56% vs. 
16.4%) of MMC. Similar to the T cells derived from mice with small tumors (Figure 
28); T cells derived from mice with large tumors (Figure 34C) expressed high levels of 
GrB before or after MMC stimulation. Similar trends were observed for the expression 
of CD69 (Figure 34D). CD8+CD69+ T cells were increased from 63% to 79%, when 
stimulated with irradiated MMC. CD4+CD69+ T cells were also increased from 6.4% 
to 10%, when stimulated with MMC. There were no significant differences in the 
expression of CD69 comparing the T cells derived from mice with small tumors 
(Figure 29) and those from mice with large tumors (Figure 34D).  
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Figure 31:  The level of endogenous MDSCs is very high in the FVBN202 donors 
bearing large tumors 
The splenocytes were harvested from the MMC tumor-bearing female FVBN202 mice 
and were stained with CD11b and Gr1 antibodies to determine the level of endogenous 
splenic MDSCs. The figure represents a very high CD11b+Gr1+ MDSC level (upper 
right quadrant). Both the percent total and percent gated values are being shown in the 
data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
118 
 
Figure31
 
 
119 
 
Figure 32:  Ex vivo expansion of splenocytes of FVBN202 donors bearing large 
tumors using the sequential (IL-7/IL-15→IL-2) gamma chain cytokines 
Spleens harvested from MMC-tumor bearing (tumor size> 1000mm³) female FVBN202 
mice were crushed and processed to yield single cell suspension which were subjected 
to a 6-day expansion with the sequential common gamma chain cytokines. Cell counts 
were determined by trypan blue exclusion. 
120 
 
Figure 32 
 
121 
 
Figure 33: Ex vivo expansion of T cells of FVBN202 donors bearing large tumors 
using the sequential (IL-7/IL-15→IL-2) gamma chain cytokines 
Flow cytometry analyses of the percent total population of CD8+ and CD4+ T cells 
before and after the expansion with the sequential common gamma chain cytokine 
formulation. 
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Figure 34: Production of IFN-γ, perforin and granzyme B as well as the expression 
of CD69 by the ex vivo expanded T cells harvested from FVBN202 donors bearing 
large tumors  
The ex vivo expanded T cells were cultured alone or with irradiated MMC in the ratio of 
10:1 for 24 hours and stained with CD8, CD4 and specific antibodies against various 
surface and internal molecules which are considered to be the marker of anti-tumor 
responses. Fluorescence for 100,000 viable cells was analyzed by flow cytometry. (A) 
represents MMC-induced IFN-γ production by CD8+ and CD4+ T cells. (B) perforin 
production by both CD8+ and CD4+ T cells. (C) Granzyme-B production by both 
CD8+ and CD4+ T cells. (D) expression of CD69 by both CD8+ and CD4+ T cells 
upon MMC stimulation. 
124 
 
Figure 34 
 
 
125 
 
 
 
 
 
 
 
 
 
126 
 
 We also tried to compare the phenotypic distribution of freshly isolated and the ex vivo 
expanded T cells. It is clear from the data that the ex vivo expanded CD8+ T cells were 
of effector and effector/memory while CD4+ T cells were of effector and 
central/memory phenotypes (Figure 35) similar to what was detected when T cells were 
isolated from FVBN202 donors bearing small tumors and expanded with the sequential 
gamma chain cytokines (Figure 24). The ex vivo expanded T cells showed 56% 
effector, 16% effectors/memory, 22% central/memory, and 4% naïve phenotypes 
(Figure 35). The MFI for CD44 was 30.9 which was over 6 fold higher than that 
expressed in CD8+ T cells expanded with the alternating common gamma chain 
cytokines (Figure 5). The CD4+ T cells consisted of 26% effector, 10% 
effector/memory, 60% central/memory, and 3.5% naïve phenotypes. The MFI for CD44 
was 33.1 which was 4-5 fold higher than that expressed in CD4+ T cells expanded with 
the alternating common gamma chain cytokines (Figure 5). Stimulation of these T cells 
with irradiated MMC, in vitro, did not change the proportion of T cell phenotypes 
(Figure 35). These phenotypic distributions remained the same after MMC stimulation.  
Ex vivo expansion of T cells with the sequential common gamma chain cytokines 
render them refractory to MDSCs in vivo and generate long term memory 
responses against mammary tumors 
Since CD8+ T cells harvested from donors with large or small tumors showed 
predominant effector and effector/memory phenotypes upon expansion with the 
sequential gamma chain cytokines, we hypothesized that presence of effector/memory T 
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cells might protect the mice against recall tumor challenge and might also provide 
protection against relapsed tumors not expressing neu (ANV). To test our hypotheses, 
FVBN202 recipients were inoculated with 5 million MMC for the second time on day 
23 after the first inoculation without receiving cyclophosphamide or AIT. Control naïve 
mice were inoculated with an equal number of MMC cells. Figure 36A shows that all 
animals (n=3) rejected the recall tumor challenge within 14 days. Control mice 
developed tumors, as expected.  To determine whether memory T cell responses might 
also protect the mice against neu negative relapsed ANV tumor cells, animals were split 
into two groups. Group 1 was inoculated with 4 million ANV on the contralateral side, 
13 days after rejecting the recall MMC, and with 5 million MMC (3rd challenge) 11 
days after ANV challenge. Group 2 was only challenged with ANV on the contralateral 
side. The control group was inoculated with an equal number of ANV cells only. 
Figure 36B shows complete rejection of MMC and significant inhibition of ANV 
compared to the control group. Group 2 also showed inhibition of ANV compared ANV 
control mouse, though to a lesser degree compared to those inoculated with MMC, 
simultaneously. In order to determine phenotypic distribution of T cells in these 
recipient mice as well as the anti-tumor efficacy against MMC and ANV in vitro, 
animals were sacrificed and their splenocytes were analyzed. Figure 37 represents the 
phenotypic distribution of the T lymphocytes derived from the spleen of the animal 
which received AIT and were challenged with MMC (2nd inoculation) and ANV. When 
sacrificed the ANV tumor was about 600mm³. The data show predominant effector 
phenotypes for both CD8+ and CD4+ T cells.  
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In order to confirm reactivity of the T cells with both MMC and ANV, animals that 
were challenged with MMC and ANV (group 1) were sacrificed when the ANV tumor 
was about 74 mm³. Figure 38A shows the level of CD11B+Gr1+ MDSCs in the spleen 
of the recipient mouse, accounting for 4.24% of the gated granulocyte region and 1.12% 
of the total population. Gated CD11B+ population showed 5.67% Ly6G+Ly6C- and 
17.93% of Ly6G-Ly6C+ as well as 12.87% of Ly6G+Ly6C+ population. As shown in 
Figure 38B T cells showed an increased cytotoxicity against MMC (viability of MMC 
reduced from 72.91% in the absence of T cells to 62.01% in the presence of T cells). T 
cells also showed an increased cytotoxicity against CFSE-labeled ANV (Figure 38C; 
from 84.19% in the absence of T cells to 51.88% in the presence of T cells).  
Protein ELISA was conducted on the serum collected from the animals which received 
tumor challenge followed by AIT and successfully rejected the tumor and showed 
memory responses. 5 and 50 fold dilution series of the serum was prepared for the 
ELISA; no antibody mediated response towards the tumor antigen was detected in these 
animals (data not shown). 
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Figure 35: Phenotypic distribution of the ex vivo expanded T cells harvested from 
FVBN202 donors bearing large tumors and expanded with the sequential common 
gamma chain cytokines  
The ex vivo expanded T cells were stained with CD44, CD62L and CD8/CD4 
antibodies and fluorescence of 100,000 viable cells was analyzed by flow cytometry.  
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Figure 36:  Ex vivo expansion of T cells with the sequential common gamma chain 
cytokines generate long term memory responses against mammary tumors 
The animals represented in Figure 22, when successfully rejected the primary tumor 
after receiving AIT with the ex vivo expanded T cells were further re-challenged with 5 
million of MMC (A). This time no CYP treatment or AIT was given to the animals. On 
day 50 they received 4 million of ANV on the contralateral side and lastly on day 61, 
one of them received a 3rd MMC re-challenge on the contralateral side of the previous 
inoculation (B).  
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Figure 37: Phenotypic distribution of T cells derived from the AIT recipients  
The animal which received the second MMC challenge and ANV challenge was 
sacrificed when the ANV tumor reached 600 mm³ volume and splenocytes were 
harvested. The freshly isolated splenocytes were stained with CD44, CD62L and 
CD8/CD4 antibodies. The phenotypic distribution was analyzed by flow cytometry. It 
showed marked resemblance with the phenotypic distribution of the freshly isolated 
donor’s lymphocytes. 
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Figure 38: Presence of MDSCs in the spleen of the AIT recipients and anti-tumor 
efficacy of their T cells against MMC and ANV 
The recipient of AIT which received the ANV and the third MMC challenge was 
sacrificed when the ANV tumor reached 76mm³ and the MMC tumor was about to 
disappear (10mm³), the splenocytes were stained for detection of endogenous MDSCs 
(A) and to test their cytotoxic potential against MMC (B) or ANV (C).  
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CHAPTER 4 Discussions 
 
Adoptive immunotherapy (AIT) includes isolation of lymphocytes from cancer patients, 
expansion of tumor-reactive T cells ex vivo and infusion of these tumor-reactive T cells 
back into the patient (45). Current protocols for AIT of cancers utilize the ex vivo 
expansion of tumor-reactive T cells in the presence of T cell growth factors such as IL-2 
or other pharmacological agents to generate a large number of such immune effector 
cells (66). Recently, common gamma chain cytokines including IL-7, IL-15, and IL-21 
have been used for the expansion of T cells (66-68). Previous pre-clinical reports have 
suggested that the antigen-sensitized CD8+ T cells exhibit different trafficking and 
phenotypic distribution as well as functional attributes when exposed to various 
common receptor gamma chain cytokines. In the present study, we conducted 
comparative analyses of two different cytokine regimens used in our laboratory for the 
expansion of tumor-reactive T cells for AIT of breast carcinoma. We have recently used 
the alternating (IL-7/IL-15→IL-2→IL-7/IL-15) and sequential (IL-7/IL-15→IL-2) 
common gamma chain cytokine formulations for the ex vivo expansion of the 
autologous T cells derived from the FVBN202 transgenic mouse model of Her-2/neu 
positive breast carcinoma. In addition to determining the MDSC sensitivity of T cells 
expanded with these two different cytokine regimens, we also determined whether the 
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state of tumor burden during early or late tumorigenesis may affect the anti-tumor 
efficacy of donor T cells after reintroduction into the tumor bearing animals. 
Alternating and sequential common gamma chain cytokines expand tumor-
reactive T cells ex vivo 
We have previously reported that B/I activation of the neu-specific high affinity T cells 
derived from wild type FVB mice, and expansion in the presence of the alternating 
common gamma chain cytokines enhanced anti-tumor efficacy of the T cells in vitro. 
However, AIT using these T cells protected FVBN202 mice against challenge with the 
neu positive MMC, only when combined with the depletion of MDSCs in vivo (37). In 
the present studies we used FVBN202 transgenic mice as donors of low affinity T cells 
against neu positive MMC. We found that the alternating and sequential common 
gamma chain regimens ex vivo expanded tumor-reactive T cells, as evidenced by an 
enhanced tumor-induced IFN-γ production as well as cytotoxicity against MMC in 
vitro. These data argue against the notion that tumor-bearing FVBN202 animals are 
tolerant to their tumor antigens because they harbored pre-existing tumor-specific T 
cells that were expanded ex vivo. A recent report on pre-existing Her-2/neu-specific 
immune responses in breast cancer patients (69) is consistent with our observation and 
both argue against the existence of immunological tolerance in cancer patients. 
T cells expanded with the sequential common gamma chain cytokines showed 
comparable expansion and enhanced in vitro cytotoxicity but had a lower ratio of 
CD8+ to CD4+ T cells, lower production of the tumor-induced IFN-γ and a higher 
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proportion of apoptotic T cells compared to those expanded with the alternating 
common gamma chain cytokines regimen 
The alternating and sequential gamma chain cytokine formulations were equally 
effective in fold expansion of T cells, regardless of the status of tumor burden of the 
donors. However, these two regimens had differential effects on the expansion of CD4+ 
and CD8+T cells. While the alternating formulation results comparable yield of CD8+ 
and CD4+ T cells, the sequential formulation preferentially expands CD4+ T cells. The 
expansion pattern revealed that the alternating gamma chain cytokine formulation 
supported 9.2 fold and 3.4 fold expansion of the CD8+ and CD4+ T cells such that at 
the end of the expansion the proportion of both subsets were similar. With sequential 
cytokine regimen abundance of CD4+ T cells were maintained, regardless of the status 
of tumor burden in the donors. However, fold expansion of CD8+ and CD4+ T cells 
with the sequential gamma chain cytokines was lower when donors had small tumor 
burdens.  
Despite the lower ratio of CD8+ T cells over CD4+ T cells and greater numbers of 
apoptotic T cells following the expansion with sequential gamma chain cytokines, these 
T cells showed greater cytotoxic effects on MMC tumor cells in vitro.  This greater 
cytotoxicity was associated with lower titer of tumor-induced IFN-γ production by these 
T cells compared to those expanded with the alternating gamma chain cytokines (3500 
pg/ml vs. 30,000 pg/ml). Flow cytometry analysis revealed that tumor-induced IFN-γ 
production was evident in CD8+ T cells but not in CD4+ T cells. These data suggest the 
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importance of IFN-γ-independent mechanisms of tumor killing such as 
perforin/granzyme B production by the tumor-reactive T cells. While freshly isolated 
CD8+ and CD4+ T cells from FVBN202 mice showed minimal perforin production 
(less than 3%) upon stimulation with MMC in vitro, majority of the ex vivo-expanded T 
cells produced perforin in response to MMC stimulation  (6-84% of CD8+ T cells and 
0.56%-16% of CD4+ T cells). T cells isolated from animals with small tumor burdens 
and expanded with the sequential gamma chain cytokines also showed a higher 
percentage of CD8+Prf+ T cells compared to freshly isolated T cells (2-6% vs. 1.5%), 
though less than T cells derived from the donors with large tumor burden. All T cells 
showed high levels of granzyme B production regardless of cytokine formulation or 
tumor burden in the donors. We have previously reported that high affinity T cells can 
reject neu positive MMC tumor cells that lack expression of the receptor for IFN-γ, 
suggesting the existence of IFN-γ-independent mechanisms of tumor rejection by T 
cells (65). Significant in vitro tumoricidial activity of T cells expanded with sequential 
gamma chain cytokines was evident regardless of the status of tumor burden in the T 
cell donors. Others also reported that the presence of tumor-specific IFN-γ has been 
producing T cells was not correlated with objective clinical responses in patients with 
melanoma (70). Importantly, IFN-γ found to render some tumors, including uveal 
melanoma cells, resistant to granule-mediated lysis by cytotoxic lymphocytes (71). It is 
evident from these studies that sequential common gamma chain cytokine formulation 
supports expansion of tumor reactive T cells that can preferentially induce IFN-γ-
independent mechanism of tumor regression. 
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Sequential common gamma chain cytokine regimen was more efficient than the 
alternating common gamma chain cytokine formulation for the expansion of 
effector and effector/memory CD8+ T cells as well as effector and central/memory 
CD4+ T cells 
For effective and successful AIT, T cells should possess the effector function and 
homing abilities to lymph nodes to induce tumor regression and protection from future 
recurrence (50). The major cytotoxic function of the CD8+ T cells demands direct 
cellular contact with the target cells. To induce tumor specific cell death, the effector 
CD8+ T cells should reach the tumor site from blood.  This potential extravasation 
capacity depends on their ability to adhere to endothelial cells while withstanding 
hydrodynamic shear stresses exerted by flowing blood. The tethering and rolling 
mechanism is governed by the selectin family (51). According to Klebanoff et al, in the 
presence of IL-15, CD8+ T cells differentiated to the central/memory phenotype while 
IL-2 preferentially supported effector and effector/memory CD8+ T cells (72). As 
expected, the alternating gamma chain cytokine formulation maintained CD8+ and 
CD4+ central memory phenotypes after a 6-day expansion (CD8+ T cells: from 51.4% 
to 53.3% and CD4+T cells: from 58% to 40%) with small increases in effector 
phenotypes (CD8+ T cells: 2.2. fold increase and CD4+T cells: 1.3 fold increase). 
Overall, central memory and effector phenotypes were abundant after the expansion 
with alternating gamma chain cytokines. This regimen caused a marked reduction of 
naïve T cell population for the CD8+ subsets. On the other hand, the sequential 
common gamma chain cytokine formulation supported the expansion of CD8+ effector 
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and effectors/memory phenotypes, regardless of tumor burden of the donors. However, 
this formulation provided a different protection for CD4+ T cells such that central 
memory phenotypes were the most abundantly expanded cells. Given the expression of 
MHC class I but not MHC class II by the tumor cells, CD8+ T cells are expected to play 
a more important role against MMC breast tumors than CD4+ T cells. This prediction is 
supported by our observation that tumor-specific IFN-γ and perforin productions were 
markedly increased in CD8+ rather than in CD4+ T cells upon stimulation with MMC 
tumor cells in vitro. In addition, a higher frequency of CD8+ effector T cells with the 
sequential gamma chain cytokines compared to those with the alternating gamma chain 
cytokines (44-56% vs. 16.8%) was associated with greater tumoricidial activity of T 
cells in vitro. Importantly, the number of the CD44 receptors per CD8+ T cells was 
greater with sequential gamma chain cytokines compared to those with alternating 
gamma chain cytokines (MFI: 30.9 vs. 5.6). Expression of CD44 has been shown to be 
the most potent stimulator of Fas ligand expression on human T cells (52) which in turn 
may induce apoptosis in Fas positive target cells. We have already shown the 
expression of Fas in MMC tumor cells (65). These data suggest that CD8+ effector T 
cells may work better against the tumor cells compared to CD8+ central memory T 
cells. In fact in vivo tumor challenge studies further confirmed higher efficiency of 
CD8+ effector T cells in tumor rejection. While AIT by means of T cells expanded with 
the alternating gamma chain cytokines provided no protection against tumor challenge, 
those expanded with the sequential common gamma chain cytokines provided complete 
protection against tumor challenge even without depletion of MDSCs in vivo. These 
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differences in the efficiency of T cells were related to different gamma chain cytokine 
formulation rather than the status of tumor burden in the donors, because in both cases 
T cells were derived from animals bearing large tumors. Importantly, T cells grown 
with the sequential common gamma chain cytokines generated long-term memory 
responses not only against MMC tumor cells but also to some extent against challenge 
with the neu antigen negative ANV relapsed tumors without need for 
cyclophosphamide treatment because of the reconstitution of tumor-reactive T cells 
following AIT. Such T cell reconstitution was confirmed by phenotype analysis of T 
cells derived from the recipient animals after the rejection of recall tumor challenge. All 
the animals showed high levels of CD8+ effector T cells (26.3%) compared to those 
derived from the donors prior to the expansion ex vivo (6-7%). These T cells also 
showed anti-tumor efficacy against MMC and ANV in vitro without further expansion 
ex vivo. These findings are consistent with previous reports showing that loss of 
expression of the lymphoid homing molecules and acquisition of CD44 expression can 
be associated with increased anti-tumor effects of adoptively transferred T cells (45). 
Status of tumor burden in FVBN202 donors was found to have significant impact on the 
efficacy of tumor-specific T cells in vitro. Compared to CD8+ T cells derived from 
animals with small tumor burden, those derived from animals with large tumor burden 
and expanded with the sequential gamma chain cytokines showed higher levels of 
tumor-induced IFN-γ (30% vs. 6.5%) and perforin (84% vs. 6.15%) production as well 
as a higher proportion of CD44+ effector phenotypes (56% vs. 44%). Higher efficacy of 
these T cells was also confirmed by showing that T cells derived from donors with large 
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tumor burden and expanded with the sequential gamma chain cytokines protected 
animals against primary and recall tumor challenge whereas those derived from donors 
with small tumor burden and expanded with the same sequential gamma chain cytokine 
protocol protected animals against primary tumor challenge but whether or not they 
may protect animals against recall tumor challenge remains to be determined.  
Higher anti-tumor efficacy of T cells expanded with the sequential gamma chain 
cytokines compared to alternating gamma chain cytokines was observed despite the 
higher levels of apoptotic cells and lower proportion of CD8+ T cells over CD4+ T 
cells. This may be related to the fact that continuous presence of IL-7 during the 
expansion (with the alternating gamma chain cytokine regimen) could protect T cells 
from apoptosis and as a result increase the frequency of T cells that are at late stage of 
differentiation and may not last long in vivo after AIT. Higher frequency of central 
memory T cells also supports this possibility. On the other hand, continuation of culture 
with IL-2 (with the sequential common gamma chain cytokines) results in apoptosis of 
T cells that are at late stages of differentiation and rescues those at early stages of 
differentiation that could undergo further differentiation in vivo after AIT. Higher 
frequency of apoptotic T cells as well as lower proportion of CD8+ central memory T 
cells supports this possibility. However this was only the case for CD8+ T cells and 
could not explain high proportion of CD4+ central memory T cells. Therefore, a key 
element would be whether T cells grown with the sequential gamma chain cytokines 
may acquire resistance to inhibitory function of MDSCs, as suggested by in vivo 
efficacy of AIT by means of these T cells in the absence of MDSC depletion. 
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Sequential common gamma chain cytokine protocol facilitates differentiation and 
expansion of tumor-reactive T cells that are refractory to the inhibitory effects of 
MDSCs 
MDSCs are known to be a major contributor in tumor-induced immune suppression. 
Gabrilovich et al. have shown antigen specific contact-dependency of these cells. 
MDSCs did exert a detrimental effect on the number of IFN-γ producing CD8+ T cells 
in response to specific peptides presented by MHC class I (35). Other reports reveal that 
MDSCs may work through downregulation of TCR zeta chain and can cause 
dysfunction of T cells described in cancer, infectious diseases and autoimmune 
disorders. Alternatively, their suppressive function may be dependent on their 
derivation from a chronically inflamed environment (36). Our previous work in 
FVBN202 transgeic mouse model of breast carcinoma showed that MDSCs inhibit T 
cell activation in a contact-dependent fashion (37). 
In vitro co-culture assays showed that T cells expanded with the sequential gamma 
chain cytokines were refractory to MDSCs, as evidenced by unaltered production of the 
tumor induced IFN-γ, perforin, granzyme B, or expression of the early activation 
marker CD69. Importantly, the presence of MDSCs did not inhibit the tumor killing 
function of T cells in vitro. Given that the T cell inhibitory function of MDSCs have 
been reported by using CD3 activation or tumor-induced activation in vitro, it is likely 
that MDSCs could inhibit activation rather than effector function of T cells. Therefore, 
they would be expected to inhibit naïve and central memory T cells rather than already 
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activated effector T cells. A higher proportion of CD8+ effector T cells with the 
sequential gamma chain cytokines compared to those with the alternating gamma chain 
cytokines support this possibility. In order to test this possibility we should sort effector 
and central memory T cells and perform in vitro suppression assays in the presence or 
absence of MDSCs. These experiments will determine whether only CD44+ effector T 
cells are refractory to MDSCs and higher proportion of these phenotypes within the 
expanded T cells cause them to be refractory to MDSCs. In line with our observation, 
other groups reported that MDSC-mediated down regulation of L-selectin to be the 
major cause of T cell suppression as T cells must have L-selectin (high) phenotype to 
home to lymph nodes and sites of inflammation where they encounter antigen and are 
activated. This down regulation perturbs T cell trafficking patterns, thereby inhibiting T 
cell activation (41). Again, this report supports the hypothesis that CD62L+ memory T 
cells are more sensitive to MDSCs than CD62L- effector T cells. 
Recently, there have been several reports on strategies to overcome MDSCs. A previous 
pre- clinical report suggests the in vivo administration of all-trans-retinoic acid can 
eliminate MDSCs (73). All-trans-retinoic acid is a naturally occurring isomer of retinoic 
acid capable of causing differentiation of a human leukemia cell line and acute 
promyelopoetic leukemia cells. In vitro experiments with all-trans-retinoic acid show 
marked success in removing MDSCs in humans and mice. Combined application of this 
compound and cancer vaccines showed reduced immune suppression and better efficacy 
of the vaccines (73). Anti-inflammatory triterpenoids such as the synthetic C-28 methyl 
ester of 2-cyano-3, 12-dioxooleana-1,9,-dien-28-oic acid (CDDO-Me) have been 
147 
 
proven to abrogate the immune suppressive functions of MDSCs (74). Other therapeutic 
strategies involve application of cytokines, drugs and antibodies for elimination of 
MDSCs. Nowak et al. showed that anti- mitotic Gemcitabine can maintain tumor 
specific CD8+ and CD4+ T cells, preferentially reducing the B cells (75). Based on 
Nowak’s observation, Suzuki et al. tested the application of Gemcitabine, a common 
chemotherapeutic agent, along with immunotherapy for neutralizing the 
immunosuppressive effects of MDSCs. Gemcitabine HCL (GEM 2’-deoxy-2’,2’-
difluorocytidine monohydrochloride) is a base analogue of cytidine that can block DNA 
synthesis in the S-Phase thereby stopping cell cycle progression (76). Though all these 
strategies achieved partial success, none of them could observe complete reduction of 
MDSCs. The novel cytokine regimen that we have established can successfully make T 
cells refractory to the inhibitory effects of MDSCs. The ex vivo expanded T cells can 
exhibit marked anti-tumor efficacy in vitro as well as in vivo even in presence of 
MDSCs. They can even show memory responses without elimination of endogenous 
MDSCs. The exact mechanism by which the T cells can overcome the effects of 
MDSCs is not known, but one report suggests that Ox-40 ligation can break T cell 
anergy and can restore the proliferative capacity of tumor reactive T cells (77).   
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CONCLUSIONS 
1) T cell expansion with the sequential common gamma chain cytokines results in 
comparable expansion, enhanced in vitro cytotoxicity, a lower ratio of CD8+ over 
CD4+ T cells, lower levels of tumor-induced IFN-γ production and poorer viability 
of the expanded T cells in comparison to the T cells expanded by alternating gamma 
chain cytokines. 
2) The alternating common gamma chain cytokine formulation supports preferential 
differentiation of central/memory phenotypes and effector phenotype of T cells but 
the sequential gamma chain cytokine regimen supports differentiation of effector and 
effector/memory phenotypes of CD8+ T cells as well as effector and central/memory 
phenotype of CD4+T cells. The latter increases the number of CD44 receptors on 
CD8+ and CD4+ T cells. 
3) T cells expanded with the sequential common gamma chain cytokines can protect 
animals from primary neu positive tumor challenge and can exhibit strong memory 
responses against neu positive and neu negative tumor challenge.  
4) The anti-tumor efficacy of the isolated T cells after the expansion depends on the 
status of tumor burden of the donors in addition to the cytokine regimen. T cells 
harvested from donors bearing larger tumor burden show greater anti-tumor efficacy 
in terms of increased production of IFN-γ and perforin and exhibiting a higher 
percentage of CD44+ effector T cell phenotypes. 
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5)  T cells expanded with the sequential common gamma chain cytokines are refractory 
to MDSCs whereas those expanded with the alternating gamma chain cytokines are 
susceptible to MDSCs. 
 
The major observations of this study are reproducible and have been repeated 3-4 
times. The underlying mechanisms of some of our observations need further 
investigation. Thus the future directions of this investigation include: 
1) To determine which phenotype of the ex vivo expanded T cell is most effective 
in overcoming tumor escape and is refractory to MDSCs. 
2) To determine whether T cells harvested from donors with low tumor burden can 
exhibit memory responses after the expansion with sequential gamma chain 
cytokines. 
3) To examine the cytokine-induced expression of receptors (Ox-40/Ox-40L) on T 
cells that may render them refractory to MDSCs. 
4)  To determine the therapeutic efficacy of sequential common gamma chain 
cytokines-expanded T cells against spontaneous and transplanted mammary 
tumors.  
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